Single-Cell Landscape and Tumor-Immune Interactions in Colon Cancer: Unveiling Therapeutic Targets
This single-cell RNA sequencing report delineates the cellular and molecular landscape of colon cancer by comparing tumor and adjacent normal tissues. We observed a clear distinction between malignant aneuploid epithelial cells and diploid non-malignant cells, accompanied by significant remodeling of the tumor microenvironment. Key findings include increased infiltration of diverse immune and stromal cell populations, with notable shifts towards immunosuppressive T cell and macrophage phenotypes. Furthermore, distinct cell-cell interaction networks and condition-specific surfaceome markers highlight dysregulated communication pathways and potential therapeutic vulnerabilities in tumor cells, cancer-associated fibroblasts, and tumor-associated macrophages.
Contents
- Dataset overview
- UMAP Visualization of Single-Cell Transcriptomic Data by Condition, Sample, and Cell Type Annotations
- UMAP Visualization of Key Marker Gene Expression and Minor Cell Type Annotation
- Celltype Subtype Marker Expression Validation in Colon Single-Cell RNA-seq Data
- Copy Number Variation Analysis of Intestinal Epithelial Cells and Unassigned Cells
- UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples
- Colon Tissue Minor Cell Type Population Analysis
- T Cell Subset Population Dynamics in Colorectal Cancer
- Macrophage Subset Population Shifts in Colon Cancer
- Differential T Cell Subset Proportions in Colon Tumor vs. Adjacent Normal Tissue
- Macrophage (M1) Subset Proportion in Colon Tumor vs. Adjacent Normal Tissue
- Ploidy Population Analysis of Intestinal Epithelial and Unassigned Cells in Colon Tissue
- Colon Cancer Cell-Cell Interaction Landscape: Tumor vs. Adjacent Normal
- Adjacent Normal 및 종양 조직의 세포-세포 상호작용 분석
- Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Colon Tissue
- Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
- Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colon Tissue
- Macrophage Condition-Specific Surfaceome Markers in Colon Tissue
- Condition-Specific Surfaceome Markers in Colon Fibroblasts
- CD4 T Cell Surfaceome Markers in Colon Cancer Conditions
- Intestinal Epithelial Cells in Colon Cancer Exhibit Widespread Upregulation of Cell Cycle Genes
- Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colon Tissue
- Gene Set Enrichment Analysis across Major Cell Types in Colon Tissue
- Discussion
- Query List
0. Dataset overview
Dataset Summary
- Type: Single-cell RNA-seq data, processed by SCODA.
- Dimensions: Contains 88,124 cells and 27,779 genes.
- Species & Tissue: Human, Colon tissue.
- Conditions: The dataset includes data from 'tumor' and 'adjacent_normal' conditions.
- Major Cell Types: Key cell types identified are Intestinal Epithelial cell, T cell, Stromal cell, B cell, Myeloid cell, Endothelial cell, and Mast cell, among others.
- Ploidy Status: Cells are classified as either 'Aneuploid' or 'Diploid' based on ploidy inference.
Precomputed Results: The dataset includes precomputed results for
- Cell-Cell Interactions (CCI) per condition and sample.
- Differential Expression Gene (DEG) analysis for each celltype_minor.
- Gene Set Enrichment Analysis (GSEA) for each celltype_minor.
- Gene Ontology (GO/GSA) results for each celltype_minor.
- Copy Number Variation (CNV) estimates (obsm['X_cnv']).
1. UMAP Visualization of Single-Cell Transcriptomic Data by Condition, Sample, and Cell Type Annotations
[Analysis Visualization Results]...
Analysis Overview
This analysis provides a comprehensive visualization of single-cell RNA-sequencing data using UMAP (Uniform Manifold Approximation and Projection) plots. These plots illustrate the overall cellular landscape of the colon tissue, colored by various metadata features: disease condition (tumor vs. adjacent normal), individual samples, major cell types, minor cell types, ploidy status, and highly detailed cell type subsets. The goal is to assess the data's overall structure, the quality of cell type annotations, and the distribution of cells across different biological and technical factors.
Visual Summary
Condition
The UMAP colored by condition shows a clear separation between cells originating from 'tumor' (indigo) and 'adjacent_normal' (maroon) tissues. A large, dense cluster on the right side of the UMAP is predominantly composed of tumor cells, while adjacent normal cells are more interspersed, often co-localizing with tumor cells in some regions, but also forming distinct smaller clusters. This indicates significant transcriptional differences between cells in the tumor microenvironment and those in healthy adjacent tissue.
Sample
The sample UMAP displays a remarkable intermixing of cells from different individual samples (C103-C173) across the entire embedding. No single sample forms isolated, large clusters that dominate the landscape. This suggests effective integration of data from multiple donors, indicating that sample-specific technical variations (batch effects) have been largely mitigated, allowing true biological heterogeneity to emerge.
Celltype Major
The celltype_major UMAP reveals well-defined clusters corresponding to broad cell lineages. 'Intestinal Epithelial cell' (orange) forms a large, central cluster, consistent with its role as the tumor origin cell type. 'T cell' (teal), 'Stromal cell' (light green), 'Myeloid cell' (yellow-green), and 'B cell' (maroon) populations also form distinct clusters, reflecting their unique transcriptional profiles and demonstrating robust major cell type annotation. 'Endothelial cell' (red) and 'Mast cell' (yellow) appear as smaller, distinct groups.
Celltype Minor
The celltype_minor UMAP provides a finer resolution of cell identities within the major groups. For example, 'T cell CD4+' (dark blue) and 'T cell CD8+' (blue) are clearly resolved within the broader T cell compartment. 'Macrophage' (yellow) and 'Fibroblast' (light orange) emerge as prominent populations, further refining the immune and stromal compartments, respectively. This demonstrates the ability to distinguish functionally distinct cell populations within the major lineages.
Ploidy_dec
The ploidy_dec UMAP highlights the distribution of aneuploid and diploid cells. 'Aneuploid' cells (maroon) are predominantly concentrated within the large cluster on the right, which largely overlaps with the 'tumor' condition and the 'Intestinal Epithelial cell' cluster. 'Diploid' cells (light yellow) are widely distributed across the entire UMAP, encompassing most immune, stromal, and some epithelial cell populations. This strong association of aneuploidy with the epithelial cell compartment within tumor regions is a key finding. A small proportion of cells are labeled as 'Unclear' (dark blue).
Celltype Subset
The celltype_subset UMAP presents the highest resolution of cell type annotation, distinguishing highly specific cell populations. Within the 'Intestinal Epithelial cell' compartment, various specialized cells like 'Enterocyte', 'Goblet cell', 'Crypt cell', 'Paneth cell', and 'Tuft cell' are identified. Immune cells are further subdivided into numerous functional subsets, including various T helper cells ('Tfh', 'Th1', 'Th2', 'Th9', 'Th17', 'Th22'), 'Treg', 'T cell (Cytotoxic)', and distinct 'Macrophage' polarization states (M1, M2A, M2B, M2C, M2D). This granular annotation offers detailed insight into cellular heterogeneity.
Biological Interpretation
The UMAP visualizations collectively provide a robust overview of the cellular composition and transcriptional states within the colon tissue, differentiating between tumor and adjacent normal conditions.
- Tumor-specific Cellular States: The condition UMAP clearly shows that tumor cells drive a significant portion of the transcriptional variability, forming distinct clusters. This is expected in colorectal cancer, where malignant transformation alters gene expression in tumor cells and reshapes the surrounding microenvironment.
- Aneuploidy as a Tumor Cell Marker: The ploidy_dec UMAP provides strong evidence for identifying malignant epithelial cells. Aneuploidy, a hallmark of cancer characterized by an abnormal number of chromosomes, is predominantly found in the 'Intestinal Epithelial cell' cluster that overlaps with the 'tumor' condition. This suggests that the large 'Intestinal Epithelial cell' cluster on the right side of the UMAP predominantly represents the cancerous epithelial cells [PubMed search: aneuploidy cancer biomarker]. Other cell types, such as immune and stromal cells, consistently maintain a diploid state, as expected for non-malignant cells.
- Comprehensive Cell Type Annotation: The progressive resolution from celltype_major to celltype_subset highlights the rich cellular heterogeneity of the colon and its microenvironment. Identifying specific subsets like various T cell helper populations (e.g., Th1, Th17, Treg), diverse macrophage polarization states (e.g., M1, M2 subtypes), and specialized intestinal epithelial cells (e.g., Enterocytes, Goblet cells) is crucial for understanding their specific functions and dysregulation in disease.
- Robust Data Integration: The lack of prominent sample-specific clustering in the sample UMAP confirms the success of data integration methods. This ensures that observed cellular differences and patterns are primarily driven by biological variation rather than technical artifacts, enhancing the reliability of subsequent analyses comparing conditions or cell types across the entire dataset.
Annotation Notes
The consistency across the UMAPs – specifically, the strong alignment between the large Intestinal Epithelial cell cluster, the tumor condition, and the Aneuploid ploidy status – provides high confidence in the quality of the cell type annotations, particularly for distinguishing malignant epithelial cells from other stromal and immune cells. The granular celltype_minor and celltype_subset annotations appear biologically meaningful and are well-segregated in the embedding space, indicating accurate assignment of cell identities based on their transcriptional profiles. The effective removal of batch effects (as seen in the sample UMAP) further validates the integrity of the embedding for downstream analyses.
2. UMAP Visualization of Key Marker Gene Expression and Minor Cell Type Annotation
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the expression of a panel of known marker genes across the single-cell RNA-seq dataset on a UMAP embedding, alongside the pre-computed celltype_minor annotations. The primary goal is to assess the quality of the cell type annotations by examining if specific marker genes show enriched expression in their expected cell populations. This helps to confirm the distinct identity and spatial separation of different cell types within the UMAP landscape.
Visual Summary
The UMAP plot displays a complex cellular landscape from human colon tissue, with multiple distinct clusters representing different cell populations. The celltype_minor annotation plot reveals well-separated clusters for major immune cell types (T cells, B cells, Macrophages, NK cells, Plasma cells, Mast cells, DCs), stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells), and Intestinal Epithelial cells (Ent.Epi).
Upon examining the expression patterns of the selected marker genes:
Immune Cell Markers:
- CD3D, CD4, CD8A: These T cell markers show strong, localized expression. CD3D is broadly expressed in the T cell clusters. CD4 expression is highly enriched in the cluster labeled "T cell CD4+", while CD8A is specifically high in the "T cell CD8+" cluster, demonstrating clear separation and consistent annotation of T cell subsets.
- CD79A, MS4A1: Both are characteristic B cell markers. Their expression is concentrated in the clusters annotated as "B cell", providing robust validation for this cell population.
- MZB1: This gene, a marker for plasma cells, shows high expression in a distinct cluster that corresponds to the "Plasma cell" annotation.
- CD14, LYZ: These genes are classical markers for myeloid cells, particularly monocytes and macrophages. Their elevated expression is observed in the cluster annotated as "Macrophage", confirming the identity of this myeloid population.
Stromal and Epithelial Cell Markers:
- FBLN1: FBLN1 (Fibulin 1) expression is found in clusters corresponding to "Fibroblast" and potentially some "Smooth muscle cell" or "Endothelial" cells, consistent with its role in the extracellular matrix and association with mesenchymal lineages. GeneCards FBLN1
- NOTCH3: NOTCH3 expression is notably enriched in a small, distinct cluster, which based on the celltype_minor annotation, aligns with "Endothelial" or "Smooth muscle cell" populations. Notch signaling is critical for vascular development and smooth muscle cell differentiation. GeneCards NOTCH3
- EPCAM, MUC1: These are strong epithelial cell markers. Both genes show high and specific expression in the large cluster identified as "Intestinal Epithelial cell", confirming their epithelial origin.
- CD34: CD34 expression is localized to a few small, distinct clusters, primarily corresponding to "Endothelial" cells. CD34 is a well-known marker for endothelial cells, particularly vascular endothelial cells and also hematopoietic stem/progenitor cells. GeneCards CD34
Biological Interpretation
The UMAP plots clearly demonstrate that the celltype_minor annotations are well-supported by the expression patterns of established marker genes. Each marker gene exhibits highly restricted expression to its expected cell type cluster, indicating a high degree of specificity and accuracy in the cell type assignments.
- The distinct separation of T cell subtypes (CD4+ vs. CD8+) based on CD4 and CD8A expression, alongside pan-T cell marker CD3D, suggests robust identification of these critical immune populations.
- Similarly, the clear expression of B cell and plasma cell markers (CD79A, MS4A1, MZB1) in their respective clusters validates the differentiation trajectory within the B cell lineage.
- The localization of myeloid markers (CD14, LYZ) to macrophage clusters, and epithelial markers (EPCAM, MUC1) to intestinal epithelial cells, further confirms the accurate identification of these major cell compartments within the colon.
- The expression of FBLN1, NOTCH3, and CD34 in stromal and endothelial populations is consistent with their known biological roles in extracellular matrix, vascular development, and endothelial cell identity, respectively.
Overall, the visualizations confirm that the UMAP embedding effectively separates distinct cell populations, and the celltype_minor annotations are reliable and biologically coherent based on these classic gene markers. This robust annotation forms a strong foundation for subsequent downstream analyses, such as differential gene expression or cell-cell interaction studies.
Annotation Notes
The strong concordance between known cell type-specific marker gene expression and the celltype_minor annotations provides significant confidence in the quality of the current cell type assignments. The UMAP embedding effectively resolves distinct cell populations, and the marker gene expression patterns reinforce the biological identity of each annotated cluster. This visual validation is crucial for ensuring the interpretability and reliability of any conclusions drawn from this single-cell dataset.
3. Celltype Subtype Marker Expression Validation in Colon Single-Cell RNA-seq Data
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a dot plot illustrating the expression of selected marker genes across various celltype_subset populations identified in the single-cell RNA-seq dataset of human colon tissue. The purpose is to visually confirm the distinct identity of each cell subtype based on the specificity and abundance of its marker gene expression. The plot visualizes the mean expression level (color intensity) and the fraction of cells expressing the gene (dot size) within each celltype_subset. Only surfaceome-related markers are shown, which are often relevant for functional characterization or therapeutic targeting.
Visual Summary
The dot plot displays celltype_subset populations on the y-axis and marker genes on the x-axis. A clear block-diagonal pattern is observed, with distinct clusters of highly expressed (dark red color) and prevalent (large dot size) markers for most cell subtypes. Red boxes are drawn around these clusters, indicating genes that are highly specific to a particular cell type or a closely related group of cell types. This pattern suggests that the selected marker genes are effective at distinguishing the various celltype_subset populations. The legend on the right indicates the number of cells in each group, while the color bar and dot size legend explain mean expression and fraction of cells, respectively.
Biological Interpretation
The marker gene expression patterns largely confirm the distinct biological identities of the annotated celltype_subset populations, showing specific enrichment of known markers within their respective groups.
Intestinal Epithelial Cells
The diverse intestinal epithelial cell subtypes show highly specific marker expression:
- Crypt cells are characterized by markers such as ELF3, CDX1, CDX2, EPHB2, and notably ASCL2, a crucial transcription factor for intestinal stem cell maintenance [GeneCards].
- Enterocytes exhibit strong expression of genes like FABP1, KLF5, VIL1, MUC13, HNF4A, KRT20, and CDH17, indicative of their absorptive and barrier functions.
- Goblet cells are clearly identified by canonical mucin and trefoil factor genes, specifically MUC2, TFF3, and AGR2, consistent with their mucus-producing role.
- Microfold cells show specific expression of SPP1 (Osteopontin), a protein involved in immune responses and highly expressed in M cells [GeneCards].
- Paneth cells are distinctly marked by LYZ (Lysozyme), reflecting their antimicrobial defense role in the intestinal crypts [GeneCards].
- Tuft cells show expression of SOX9, which is associated with epithelial stemness and differentiation into various lineages including Tuft cells.
Immune Cells (Lymphoid Lineage)
- B cells (Breg, MZ, Memory) express pan-B cell markers like POU2F2 (OCT2), a key B-cell specific transcription factor [GeneCards].
- Plasma cells are clearly delineated by their unique expression of MZB1, SDC1 (CD138), and TNFRSF17 (BCMA), consistent with their role in antibody production.
- ILC1 and NK cells share expression of KLRD1 (CD94) and GZMB, reflecting their cytotoxic capabilities.
T cells
- T cell (Cytotoxic) populations are marked by CD8A and GZMB, indicating their cytotoxic effector functions.
- T cell (Treg) cells exhibit expression of CTLA4, a key immune checkpoint molecule associated with immune regulation.
- T cell (Th1) cells show STAT1 expression, consistent with their role in cell-mediated immunity.
Immune Cells (Myeloid Lineage)
- Dendritic cells (Classical, Inflammatory, Plasmacytoid) express general DC markers such as CD83, CD86, and SIRPA. Notably, DC (Plasmacytoid) cells are specifically marked by LILRA4 and TCF4, which are characteristic of this antiviral-sensing DC subtype.
- Macrophages (M1, M2A, M2B, M2C) generally express CD86 and MSR1. While these are broad macrophage markers, some differential expression patterns hint at distinct activation states, though comprehensive M1/M2 discrimination often requires a larger panel of genes.
- Mast cells are unequivocally identified by KIT (CD117) and TPSAB1 (tryptase), classic mast cell markers.
Stromal Cells
- Fibroblasts show a robust expression of collagen genes (COL1A1, COL3A1, COL6A2), DCN, LUM, PDGFRA, ACTA2, and FBLN1, consistent with their role in extracellular matrix production and tissue structural support.
- Smooth muscle cells are clearly distinguished by their expression of ACTA2 (alpha-SMA), MYH11, CNN1, and TAGLN, which are critical for muscle contraction.
Endothelial Cells
- Endothelial cells and Endothelial tip cells express general endothelial markers such as ACKR1, ANGPT2, and DLL4.
- Lymphatic Endothelial cells are specifically marked by PROX1, a master regulator of lymphatic endothelial cell identity and development [GeneCards].
Annotation Notes
The dot plot provides strong evidence supporting the quality and distinctness of the celltype_subset annotations within this AnnData object. The clear, specific expression patterns of known marker genes across most cell types indicate robust clustering and annotation. The selection of surfaceome-only markers further enhances the practical utility of these findings, as these markers are often amenable to validation by techniques such as flow cytometry or immunohistochemistry, and are potential candidates for cell-specific targeting. The consistency between observed gene expression and established biological knowledge reinforces confidence in the cell type assignments for downstream analyses.
4. Copy Number Variation Analysis of Intestinal Epithelial Cells and Unassigned Cells
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates copy number variations (CNVs) in Intestinal Epithelial cells and "unassigned" cell populations, grouped by individual samples. The primary objective is to visualize recurrent genomic amplifications and deletions and to identify potential genomic instability associated with the ploidy_dec (Aneuploid vs. Diploid) status and tumor origin. The results are presented as a heatmap showing log2(CNR) values across genomic spots for individual cells, followed by a summary heatmap and bar plot of significantly amplified cytogenetic bands and associated genes.
Visual Summary
CNV Heatmap (First Image)
The first heatmap displays log2(CNR) values across the genome for individual cell groups, colored by amplification (red) and deletion (blue).
- Ploidy Status Differentiation: A clear distinction is observed between cell groups labeled "Aneuploid" and "Diploid". Aneuploid cell groups, which are predominantly found in the upper portion of the heatmap for each sample, exhibit widespread and distinct patterns of genomic amplifications and deletions across many chromosomes. In contrast, "Diploid" cell groups (lower portion for each sample) show minimal to no significant CNVs, maintaining a relatively neutral log2(CNR) signal (white/light colors). This robustly separates cells with significant genomic instability from those with stable genomes.
- Recurrent CNV Patterns: Within the Aneuploid cell groups, several chromosomal regions show recurrent amplifications (red vertical bands) and deletions (blue vertical bands) across multiple samples (e.g., C103, C104, C105, etc.). Notable regions include amplifications on chromosome 7, 8, 11, 13, 16, 17, 19, 20, and 21, and deletions on chromosome 9, 10, 14, and 18.
- Sample Heterogeneity: While common CNV patterns exist, there is also notable heterogeneity in the specific genomic regions and their extent across different Aneuploid samples, indicating inter-patient variability in tumor genomic profiles.
- Unassigned Cells: Both "Intestinal Epithelial cell" and "unassigned" labels appear within the Aneuploid cell groups for various samples, suggesting that a subset of "unassigned" cells exhibit similar CNV patterns to the Intestinal Epithelial cells, implying potential genomic instability or tumor association for these unassigned cells.
CNV Summary Heatmap and Bar Plot (Second Image)
The second visualization provides a summary of the frequency of significant copy number alterations across cytogenetic bands for the selected samples.
- Top Amplified Regions: The bar plot on the right highlights the most frequently amplified cytogenetic bands. The top regions and their associated genes are:
- 7p12.3:7q21.12, containing the *EGFR* gene (observed in ~0.74 frequency).
- 17q12:17q21.2, containing the *ERBB2* gene (observed in ~0.53 frequency).
- 8p12:8q24.3, which includes genes like *INTS5*, *COPS5*, *DSMD1*, *DDHD2*, *EIF3E*, and *TPD52* (observed in ~0.47 frequency).
- 1q21.3:1q23.2 (observed in ~0.84 frequency).
- 19q13.43:21q21.3 (observed in ~0.42 frequency).
- Top Deleted Region: A notable deletion is observed at 9p22.2:9p13.3, which contains the *CDKN2A* gene (observed in ~0.32 frequency).
- Sample-Specific Frequencies: The heatmap on the left displays the frequency of these amplifications (0.0 to 1.0) for each cytogenetic band across the individual samples (e.g., C103, C104, C109). This shows that while some regions are frequently amplified across many samples (e.g., 1q21.3:1q23.2, 7p12.3:7q21.12), others are more prominent in specific subsets of samples.
Biological Interpretation
The analysis clearly reveals distinct genomic profiles within the selected Intestinal Epithelial cells and unassigned cells, providing critical insights into their biological states.
- Ploidy as a Marker for Malignancy: The stark contrast in CNV load between "Aneuploid" and "Diploid" cell groups strongly supports the ploidy_dec annotation as an effective discriminator. Cells classified as Aneuploid, primarily Intestinal Epithelial cells, display extensive genomic instability, a hallmark of cancer cells. This suggests that the Aneuploid Intestinal Epithelial cells represent the malignant epithelial compartment of the colon tumors. Conversely, the Diploid cell populations, showing minimal CNVs, likely represent normal intestinal epithelial cells or other non-malignant cell types within the tissue.
Key Oncogene Amplifications in Colorectal Cancer:
- _EGFR_ (Epidermal Growth Factor Receptor) Amplification (7p12.3:7q21.12): Amplification of *EGFR* is a well-established oncogenic event in various cancers, including a subset of colorectal cancers. *EGFR* activation promotes cell proliferation, survival, and metastasis. Its amplification in these cells underscores its potential role as a driver mutation in the observed tumor samples. https://www.genecards.org/cgi-bin/carddisp.pl?gene=EGFR
- _ERBB2_ (HER2) Amplification (17q12:17q21.2): *ERBB2* amplification, also known as HER2 amplification, is a significant oncogenic driver, particularly recognized in breast and gastric cancers, but increasingly identified in a subset of colorectal cancers. Similar to *EGFR*, HER2 overexpression drives cell growth and survival. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ERBB2
- 8p12:8q24.3 Amplification (including _MYC_ locus): The 8q24.3 region is known to harbor the _MYC_ oncogene, a critical regulator of cell proliferation, differentiation, and apoptosis. Amplification of this region is a frequent event in colorectal cancer and other malignancies, contributing to aggressive tumor phenotypes. While the specific genes listed (*INTS5, COPS5, DSMD1, DDHD2, EIF3E, TPD52*) are co-amplified, *MYC* is a common driver within this broad region. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098059/
Tumor Suppressor Gene Deletion:
- _CDKN2A_ Deletion (9p22.2:9p13.3): The deletion of *CDKN2A* is a very common genomic alteration across many cancer types, including colorectal cancer. *CDKN2A* encodes tumor suppressor proteins p16INK4a and p14ARF, which regulate cell cycle progression and apoptosis. Loss of *CDKN2A* function leads to uncontrolled cell proliferation. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDKN2A
- Identity of "Unassigned" Cells: The observation that some "unassigned" cells exhibit extensive CNVs, similar to the Aneuploid Intestinal Epithelial cells, suggests that these cells might also be malignant epithelial cells that were challenging to classify precisely using transcriptomic markers alone. Alternatively, they could represent a subpopulation of tumor-associated cells (e.g., tumor-infiltrating immune cells that have undergone genomic instability in response to the tumor microenvironment, though this is less common for broad CNVs). Given the Tumor origin celltype is "Intestinal Epithelial cell", it is most plausible that these are tumor-derived epithelial cells.
Annotation Notes
- This CNV analysis strongly validates the ploidy_dec annotation, demonstrating its utility in distinguishing genomically unstable (Aneuploid, likely malignant) cell populations from genomically stable (Diploid, likely non-malignant) ones within the selected cell types.
- The widespread CNVs, particularly the amplifications of known oncogenes (*EGFR*, *ERBB2*, *MYC* locus) and deletion of a tumor suppressor (*CDKN2A*), in the Aneuploid Intestinal Epithelial cells confirm their likely malignant identity and align with the Tumor origin celltype metadata.
- The presence of similar CNV patterns in a subset of "unassigned" cells alongside Aneuploid Intestinal Epithelial cells suggests that these "unassigned" cells may also be of tumor origin. This finding highlights a potential area for further investigation to refine the annotation of the "unassigned" population based on genomic features.
5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples
[Analysis Visualization Results]...
Analysis Overview
This analysis presents UMAP embeddings derived from Copy Number Variation (CNV) estimates, providing a dimensionality reduction view of the single-cell RNA-seq data. The UMAP plots are colored by various metadata features: major cell type, minor cell type, ploidy status (aneuploidy/diploidy), sample condition (tumor/adjacent normal), and individual sample IDs. This visualization helps to understand how cell types, malignancy status, and experimental conditions are structured in the CNV landscape.
Visual Summary
The UMAP projections reveal distinct patterns driven by CNV information:
Cell Type Distribution (celltype_major, celltype_minor)
- Intestinal Epithelial cells (Ent.Epi) form a large, distinct cluster in the upper-right region of the UMAP, clearly separated from other cell types.
- Immune cells (T cells, B cells, Myeloid cells, NK cells, Plasma cells) and stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells) primarily occupy the central and left-hand clusters, forming interconnected but largely distinct groupings.
- Minor cell types provide a finer resolution, showing sub-clusters within these major groups (e.g., T cell CD4+, T cell CD8+, Macrophage).
Ploidy Status (ploidy_dec)
- A striking pattern is observed with ploidy_dec. The majority of cells within the large, distinct Intestinal Epithelial cell cluster are labeled "Aneuploid" (dark red).
- Conversely, most other cell clusters, corresponding to immune and stromal cells, are predominantly "Diploid" (light yellow). A small proportion of "Unclear" cells are scattered throughout.
Condition Distribution (condition)
- The "tumor" condition (dark red) largely overlaps with the "Aneuploid" regions and the Intestinal Epithelial cell cluster, forming a prominent domain.
- Cells from "adjacent_normal" samples (purple) are more broadly distributed, primarily populating the "Diploid" clusters that contain immune and stromal cells, and also appear mixed within the epithelial cluster, likely representing normal epithelial cells.
Sample Distribution (sample)
- Cells from individual samples are distributed across the UMAP. While there is a general mixing, especially within the immune and stromal cell compartments, distinct sample-specific clustering is visible, particularly within the large "Aneuploid" / "Tumor" / "Intestinal Epithelial cell" cluster. This suggests inter-sample heterogeneity in the CNV profiles of malignant cells.
Biological Interpretation
The CNV-based UMAP provides strong biological insights into the cellular composition of the colon samples, particularly in the context of cancer:
- Malignant Cell Identification: The most prominent finding is the clear spatial segregation of the "Intestinal Epithelial cell" cluster, which overwhelmingly consists of "Aneuploid" cells and originates predominantly from "tumor" conditions. This strongly suggests that these cells represent the malignant epithelial compartment, consistent with colorectal cancer arising from epithelial cells that acquire extensive genomic copy number alterations (aneuploidy) during oncogenesis.
- Non-Malignant Compartment: Conversely, the immune (T cells, B cells, Myeloid, NK cells) and stromal cells (Fibroblasts, Endothelial, Smooth muscle cells) are largely "Diploid" and are found in both "tumor" and "adjacent_normal" conditions, indicating their role as components of the tumor microenvironment or normal colon tissue. Their distinct clustering from the aneuploid epithelial cells further validates their non-malignant identity.
- CNV as a Driving Feature: The effectiveness of CNV estimates in separating malignant epithelial cells from non-malignant cells and in distinguishing between tumor and adjacent normal conditions underscores the utility of CNV as a powerful feature for identifying cancer cells in single-cell data, even without specific marker genes.
- Inter-tumor Heterogeneity: The sample-specific patterns within the aneuploid epithelial cluster highlight the genomic heterogeneity that often exists between tumors from different patients. This variability in CNV profiles can reflect diverse evolutionary paths of tumors.
Annotation Notes
- The strong concordance between the CNV-driven UMAP structure, celltype_major/celltype_minor annotations, ploidy_dec (aneuploid vs. diploid), and condition (tumor vs. adjacent_normal) provides robust validation for the cell type assignments and the inferred malignancy status of the cells.
- The clear separation of Intestinal Epithelial cells that are aneuploid and from tumor samples from the rest of the cells is a key indicator of high-quality annotation for the primary tumor cells.
- The unassigned cells are largely diploid and dispersed among the immune/stromal clusters, suggesting they are likely non-malignant cells whose precise identity could not be determined.
- The UMAP effectively illustrates that CNV analysis can be a powerful independent method to corroborate and refine cell type annotations, especially for identifying cancer cells.
6. Colon Tissue Minor Cell Type Population Analysis
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여 대장 조직 내 인접 정상(adjacent_normal) 및 종양(tumor) 샘플에서 마이너 세포 유형(celltype_minor)의 상대적 분포를 시각화한 것입니다. 각 막대 그래프는 개별 샘플을 나타내며, 각 색상 세그먼트는 해당 샘플 내 특정 마이너 세포 유형의 상대적 비율을 보여줍니다. 이 분석은 대장암 발생 및 진행에 따른 미세환경 변화를 이해하는 데 중요한 초기 단계를 제공합니다.
Visual Summary
제공된 막대 그래프는 인접 정상 조직과 종양 조직 간의 마이너 세포 유형 구성에서 뚜렷한 차이를 보여줍니다.
인접 정상 조직 (adjacent_normal)
- Intestinal Epithelial cell (장 상피세포)이 대부분의 샘플에서 가장 큰 비율(대략 40-60%)을 차지하며, 이는 건강한 장 조직의 주요 구성 요소로서 예상되는 결과입니다.
- B cell, T cell CD4+, T cell CD8+, Macrophage, Plasma cell, Fibroblast, Endothelial cell과 같은 다양한 면역 및 기질 세포 유형이 비교적 일관된 비율로 존재합니다.
- Smooth muscle cell도 일부 샘플에서 일정 비율로 관찰됩니다.
종양 조직 (tumor)
- Intestinal Epithelial cell의 비율은 인접 정상 조직에 비해 감소하는 경향을 보이지만, 일부 샘플에서는 여전히 높은 비율을 유지하기도 하여 샘플 간 이질성이 관찰됩니다.
- T cell CD4+와 T cell CD8+를 포함한 T 세포의 비율이 인접 정상 조직에 비해 전반적으로 증가하는 경향을 보입니다.
- Macrophage와 Plasma cell의 비율 또한 종양 샘플에서 상당수 증가하는 패턴을 보입니다.
- Fibroblast (섬유아세포)의 비율이 인접 정상 조직보다 종양 샘플에서 확연히 증가하는 것이 여러 샘플에서 관찰됩니다.
- Smooth muscle cell의 비율은 종양 조직에서 인접 정상 조직에 비해 감소하는 경향을 보입니다.
- Dendritic cell, ILC, NK cell, Mast cell 등은 양쪽 조건에서 소수 세포 유형으로 존재하며, 큰 폭의 비율 변화는 뚜렷하지 않습니다.
전반적으로, 종양 미세환경은 면역 세포(특히 T 세포, 대식세포, 형질세포) 및 기질 세포(특히 섬유아세포)의 침윤이 증가하고, 장 상피세포 및 평활근 세포의 상대적 비율이 변화하는 특징을 보입니다.
Biological Interpretation
이러한 세포 집단 변화는 대장암의 복잡한 생물학적 과정과 종양 미세환경(TME)의 재구성을 반영합니다.
- 장 상피세포의 상대적 감소: 장 상피세포는 종양의 기원 세포(Tumor origin celltype)이므로, 종양 조직에서 이 세포 유형의 상대적 비율 감소는 종양 세포 자체가 줄어들었다기보다는 면역 세포 및 기질 세포와 같은 비종양성 세포의 침윤이 증가하여 전체 세포 구성에서 차지하는 비율이 상대적으로 낮아졌음을 시사합니다. 이는 면역회피 또는 종양 지지 미세환경 형성의 결과일 수 있습니다.
면역 세포 침윤 증가
- T cell (T 세포) 및 Macrophage (대식세포)의 증가는 종양 미세환경 내에서 활발한 면역 반응이 일어나고 있음을 나타냅니다. T 세포 침윤은 항종양 면역 반응의 중요한 지표이며, 특히 CD8+ T 세포는 암세포 사멸에 관여합니다 참고: PubMed search for "CD8 T cells cancer immunity". 그러나 CD4+ T 세포는 종양 억제(Th1) 또는 종양 촉진(Th2, Treg) 역할을 모두 수행할 수 있어, 특정 서브셋의 변화는 추가 분석(예: GSEA, DEG)이 필요합니다.
- Macrophage는 종양 미세환경에서 종양 관련 대식세포(TAMs)로 불리며, 종양 성장, 침윤, 전이 및 혈관 신생을 촉진하는 데 중요한 역할을 합니다 참고: GeneCards - Macrophage related genes.
- Plasma cell (형질세포)의 증가는 B 세포가 종양 미세환경에서 활성화되어 항체를 생산하는 쪽으로 분화했음을 시사하며, 이는 종양 특이적 항체 반응 또는 염증 반응과 연관될 수 있습니다.
기질 세포 변화
- Fibroblast (섬유아세포)의 유의미한 증가는 종양 미세환경에서 암 관련 섬유아세포(CAFs)의 축적을 강력히 시사합니다 참고: PubMed search for "Cancer associated fibroblasts colorectal cancer". CAFs는 세포외 기질(ECM)을 재구성하고, 성장 인자 및 면역 억제 분비를 통해 종양 성장, 전이 및 약물 내성을 촉진하는 핵심적인 역할을 합니다.
- Smooth muscle cell (평활근 세포)의 감소는 정상 조직 구조의 파괴 및 종양 세포와 다른 기질 요소에 의한 대체 현상을 반영할 수 있습니다.
이러한 세포 집단 구성의 변화는 대장암에서 종양 미세환경이 질병 진행에 중요한 역할을 하며, 종양 세포뿐만 아니라 주변 면역 및 기질 세포 간의 복잡한 상호작용이 암의 생물학을 결정한다는 것을 보여줍니다.
Clinical or Translational Implications
이러한 세포 집단 분석 결과는 대장암의 진단, 예후 예측 및 치료 전략 개발에 중요한 임상적 시사점을 제공합니다.
- 예후 바이오마커: 종양 내 T 세포 서브셋 (CD8+ T 세포 대 조절 T 세포) 또는 특정 유형의 대식세포 (M1 대 M2) 비율은 환자의 예후와 면역 치료 반응성을 예측하는 바이오마커로 활용될 수 있습니다. Fibroblast의 밀도 및 활성화 상태도 종양 진행 및 치료 저항성과 연관될 수 있습니다.
치료 표적 발굴
- 증가된 면역 세포 침윤은 면역 관문 억제제(immune checkpoint inhibitors)와 같은 면역 치료의 잠재적 효과를 지지합니다. 특히 CD8+ T 세포의 활성 증가는 긍정적인 치료 반응과 연관될 수 있습니다.
- 증가된 Fibroblast는 CAFs를 표적으로 하는 치료법(예: 섬유증 억제제, CAFs-특이적 신호 전달 경로 차단제) 개발의 근거가 될 수 있습니다. CAFs는 종양에 대한 약물 침투를 방해하고 치료 저항성을 유도할 수 있기 때문입니다.
- 종양 이질성: 샘플 간의 세포 구성 비율 이질성은 대장암의 개인별 맞춤 치료(personalized medicine)의 중요성을 강조합니다. 개별 환자의 종양 미세환경 프로파일링은 최적의 치료법 선택에 도움을 줄 수 있습니다.
7. T Cell Subset Population Dynamics in Colorectal Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a stacked bar plot visualizing the relative proportions of various T cell subsets and related innate lymphoid cells (ILCs) within the 'T cell' major population across individual samples. The samples are stratified by 'adjacent_normal' and 'tumor' conditions, allowing for a direct comparison of immune cell composition shifts in the tumor microenvironment (TME) versus healthy tissue. Each bar represents a single sample, and the colored segments indicate the percentage contribution of each specific T cell/ILC subset (e.g., T cell (Cytotoxic), T cell (Treg), ILCs) to the total T cell compartment for that sample.
Visual Summary
The stacked bar plots display the proportional distribution of 17 distinct T cell and ILC subsets across multiple samples from 'adjacent_normal' and 'tumor' tissues.
- Dominant Subsets: In both adjacent normal and tumor conditions, the T cell (Cytotoxic) and T cell (Naive) populations constitute a significant portion of the total T cell compartment.
- T cell (Naive) Reduction in Tumor: There appears to be a general trend of decreased relative abundance of T cell (Naive) populations (lightest yellow) in the tumor samples compared to adjacent normal samples.
- T cell (Treg) Enrichment in Tumor: The T cell (Treg) population (dark blue) shows a visible increase in its relative proportion within many tumor samples compared to adjacent normal tissue. This increase, though not universally dramatic across all tumor samples, is consistently present and often more pronounced in tumor samples.
- ILC and Other T cell Subsets: ILCs (various shades of red/orange) and other T helper subsets (Th1, Th2, Th9, Th17, Th22, Tfh - various shades of green/yellow-green) are present but generally represent smaller proportions. There might be a subtle increase in ILC3 (NCR+) and ILC3 (NCR-) populations in some tumor samples. NK cells (orange-yellow) maintain a relatively stable, moderate presence across both conditions.
- Sample Heterogeneity: While general trends are observable, there is some sample-to-sample variability in the exact proportions of each subset within both conditions.
Biological Interpretation
The observed shifts in T cell subset populations in the colorectal tumor microenvironment provide critical insights into the immune landscape of the disease.
- Immune Activation and Differentiation: The reduction in T cell (Naive) populations in tumor tissue suggests that T cells are actively recruited to the TME and undergo differentiation into various effector or regulatory phenotypes. This is a common feature of immune responses in inflammatory and cancerous environments.
- Treg Expansion and Immune Suppression: The most notable finding is the apparent enrichment of T cell (Treg) populations in tumor samples. Tregs are master regulators of immune tolerance, and their accumulation in the TME is a well-established mechanism by which tumors evade anti-tumor immunity. By suppressing the activity of effector T cells (like Cytotoxic T cells) and other immune cells, Tregs promote tumor growth and metastasis [1].
- Cytotoxic T Cell Presence: The sustained presence of T cell (Cytotoxic) cells in the tumor, despite Treg expansion, indicates an ongoing anti-tumor immune response. However, the effectiveness of these cytotoxic cells is likely dampened by the increased suppressive activity of Tregs. The balance between effector and regulatory T cells (Teff/Treg ratio) is crucial for effective anti-tumor immunity [2].
- Role of ILCs and Other Th Subsets: While minor, the presence and potential subtle shifts in ILCs and various T helper subsets (Th1, Th17, Th22) highlight the complexity of the immune response in colorectal cancer. For instance, ILC3s play a significant role in gut immunity and can contribute to both protective and pathogenic responses depending on the context of the TME [3]. Th1 cells are generally pro-inflammatory and anti-tumor, while Th17 cells have context-dependent roles in cancer [4].
Clinical or Translational Implications
The findings from this T cell subset analysis have several important clinical and translational implications for colorectal cancer:
- Prognostic Marker: An increased Treg infiltration in colorectal cancer is often associated with a poorer prognosis, as it signifies a more immunosuppressive TME [1]. This observation aligns with typical findings in cancer immunology.
- Immunotherapeutic Target: The enrichment of Tregs in the TME presents a potential therapeutic target. Strategies aimed at depleting Tregs, inhibiting their function, or converting them into effector T cells could enhance anti-tumor immunity and improve responses to other immunotherapies, such as checkpoint inhibitors [5].
- Teff/Treg Ratio as a Biomarker: Monitoring the Teff/Treg ratio in tumor tissue could serve as a valuable biomarker for predicting patient response to immunotherapy or for assessing disease progression.
- Developing Combination Therapies: Understanding the precise shifts in the balance of T cell subsets can inform the development of more effective combination immunotherapies that simultaneously boost effector responses and counteract immunosuppression.
References:
- Treg in Cancer Immune Evasion: UniProt. (n.d.). FOXP3 - Forkhead box protein P3. Retrieved from https://www.uniprot.org/uniprot/Q9BZS1 (FOXP3 is a key marker for Tregs, and its role in immune suppression in cancer is well-established.)
- Teff/Treg Ratio: PubMed Search: "effector T cell regulatory T cell ratio cancer prognosis" https://pubmed.ncbi.nlm.nih.gov/?term=effector+T+cell+regulatory+T+cell+ratio+cancer+prognosis
- ILC3 in Gut Immunity/Cancer: PubMed Search: "ILC3 colorectal cancer" https://pubmed.ncbi.nlm.nih.gov/?term=ILC3+colorectal+cancer
- Th17 in Cancer: PubMed Search: "Th17 cells cancer" https://pubmed.ncbi.nlm.nih.gov/?term=Th17+cells+cancer
- Treg-targeting Therapies: PubMed Search: "Treg depletion cancer immunotherapy" https://pubmed.ncbi.nlm.nih.gov/?term=Treg+depletion+cancer+immunotherapy
8. Macrophage Subset Population Shifts in Colon Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the relative proportions of different Macrophage subsets (M1, M2A, M2B, M2C, M2D) within individual samples, comparing 'adjacent_normal' colon tissue with 'tumor' colon tissue. This type of analysis is crucial for understanding the composition of the tumor microenvironment and how immune cell populations shift during carcinogenesis.
Visual Summary
The stacked bar plot presents the percentage composition of five distinct macrophage subsets for each sample, separated by tissue condition: 'adjacent_normal' and 'tumor'.
- Overall Composition: Macrophage (M1) (maroon) is a dominant subset in both 'adjacent_normal' and 'tumor' conditions across most samples, often accounting for 40-70% of the total macrophage population.
Condition-Specific Differences:
- In the 'adjacent_normal' samples, M1 macrophages tend to represent a slightly higher proportion, with M2A, M2B, M2C, and M2D subtypes making up smaller, though variable, fractions.
- In the 'tumor' samples, there is a general trend towards an increased proportion of M2-like macrophages, particularly Macrophage (M2A) (orange) and Macrophage (M2B) (light yellow), relative to the 'adjacent_normal' samples. While M1 remains substantial, the collective contribution of M2 subtypes appears to be elevated in the tumor microenvironment.
- Macrophage (M2C) (pale yellow) and Macrophage (M2D) (teal) are present in smaller proportions but also show variability between samples and conditions.
- Sample Heterogeneity: Significant sample-to-sample variability exists within both the 'adjacent_normal' and 'tumor' groups, indicating individual differences in macrophage polarization and the complexity of the immune landscape.
Biological Interpretation
Macrophages are highly plastic immune cells that play diverse roles in health and disease, including cancer. In the context of the tumor microenvironment (TME), macrophages are often referred to as Tumor-Associated Macrophages (TAMs) and can be broadly categorized into pro-inflammatory M1-like (classically activated) and anti-inflammatory/pro-tumorigenic M2-like (alternatively activated) phenotypes.
- M1 vs. M2 Polarization: M1 macrophages are generally associated with anti-tumor immunity, promoting phagocytosis, antigen presentation, and the secretion of pro-inflammatory cytokines. In contrast, M2 macrophages are typically involved in wound healing, angiogenesis, tissue remodeling, and immune suppression, all of which can support tumor growth and metastasis. The observed shift towards a higher proportion of M2-like macrophages (M2A, M2B) in colon tumor tissue is consistent with the known role of TAMs in creating an immunosuppressive and pro-tumorigenic environment. PubMed Search: M1 M2 macrophages cancer
Specific M2 Subtypes:
- Macrophage (M2A): Often induced by IL-4 and IL-13, associated with allergic responses, parasitic infections, and tissue repair. In cancer, they contribute to fibrosis and tumor growth.
- Macrophage (M2B): Induced by immune complexes and TLR agonists, they can produce both pro- and anti-inflammatory mediators. Their increased presence in tumors can contribute to immune dysregulation.
- Macrophage (M2C and M2D): M2C (induced by IL-10 and glucocorticoids) are strongly immunosuppressive and promote tissue remodeling. M2D, also known as Tie2-expressing macrophages, are highly pro-angiogenic and are linked to tumor progression.
- The persistence of M1 macrophages even within tumor samples highlights the dynamic and heterogeneous nature of the immune response in cancer. It suggests that while the tumor microenvironment favors M2 polarization, some level of anti-tumor immune activity might still be present or potentially recoverable. The balance between these opposing macrophage phenotypes is critical in determining disease progression.
Clinical or Translational Implications
The differential distribution of macrophage subsets between normal and tumor colon tissue carries significant clinical implications:
- Prognostic Biomarkers: A higher proportion of M2-like macrophages, particularly M2A and M2B, within the tumor could serve as a prognostic indicator for more aggressive disease or poorer patient outcomes in colon cancer. The M1:M2 ratio is often considered a critical determinant of clinical prognosis.
- Therapeutic Targets: The observed M2 polarization in tumors suggests that these macrophage subsets are promising therapeutic targets. Strategies could include:
- Repolarization: Developing agents to reprogram pro-tumorigenic M2 macrophages back to an anti-tumorigenic M1 phenotype.
- Depletion: Directly targeting and depleting specific M2 macrophage subsets that promote tumor growth and metastasis. GeneCards: Macrophage M2
- Immunotherapy Enhancement: Modulating macrophage populations could enhance the efficacy of existing immunotherapies, such as checkpoint inhibitors. Combining macrophage-targeting therapies with other immunotherapeutic approaches may yield synergistic anti-tumor effects.
- Personalized Medicine: Given the observed sample-to-sample heterogeneity, characterizing the specific macrophage landscape in individual patients could guide personalized treatment strategies. Patients with a predominantly M2-polarized TME might benefit more from macrophage-targeting interventions.
9. Differential T Cell Subset Proportions in Colon Tumor vs. Adjacent Normal Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportional differences of specific T cell subset populations within colorectal tumor tissue compared to adjacent normal tissue. Boxplots are utilized to visualize the distribution of cell type proportions for T cell subsets where statistically significant differences (p-value ≤ 0.1, with some stricter cutoffs observed) were identified between the 'tumor' and 'adjacent_normal' conditions. This provides insights into how the immune cellular landscape, specifically T cell compartments, is altered in the tumor microenvironment.
Visual Summary
The boxplots illustrate the proportions of five T cell subset populations: Th22, unassigned, Th2, ILCreg, and Treg, across 'tumor' and 'adjacent_normal' conditions.
- Th22 cells: Show significantly higher proportions in tumor tissue compared to adjacent normal tissue (p ≤ 0.05). The median proportion in tumor is approximately 2.5-3%, while in adjacent normal it is around 1-1.5%.
- Unassigned cells: Display a significantly higher proportion in adjacent normal tissue (p ≤ 0.05) than in tumor tissue. The median proportion in tumor is close to zero, whereas in adjacent normal, it is slightly above zero, with several outliers having higher proportions.
- Th2 cells: Show a trend towards higher proportions in adjacent normal tissue compared to tumor tissue, though the p-value of 0.07 is slightly above the typical 0.05 significance cutoff.
- ILCreg cells: Exhibit significantly higher proportions in tumor tissue compared to adjacent normal tissue (p = 0.05). The median proportion in tumor is around 0.5-1%, and in adjacent normal, it is closer to 0.
- Treg cells: Demonstrate a highly significant increase in tumor tissue proportions compared to adjacent normal tissue (p ≤ 0.01). The median Treg proportion in tumor is around 12-13%, while in adjacent normal it is approximately 8-9%.
Biological Interpretation
The observed shifts in T cell subset proportions provide critical biological insights into the immune microenvironment of colon cancer:
- Increased Th22 cells in Tumors: Th22 cells are a subset of CD4+ T cells that primarily produce IL-22, which is involved in epithelial barrier integrity, tissue repair, and inflammation. In cancer, IL-22 has complex roles, sometimes promoting tumor growth and survival by inducing proliferation and anti-apoptotic pathways in cancer cells, or by supporting tumor-associated inflammation [1, 2]. Their increased presence in colon tumors could suggest a pro-tumorigenic inflammatory environment or an attempt at tissue repair that can be hijacked by cancer.
[1] PubMed search for "IL-22 colon cancer"
[2] GeneCards entry for IL22
- Increased ILCreg cells in Tumors: Regulatory ILCs (ILCreg) are a less extensively characterized subset of innate lymphoid cells. However, their "regulatory" designation suggests a potential role in immune suppression, analogous to regulatory T cells. An increase in tumor tissue implies that these cells might contribute to the immunosuppressive microenvironment, hindering effective anti-tumor immune responses.
- Highly Significant Increase of Tregs in Tumors: Regulatory T cells (Tregs) are CD4+ T cells crucial for maintaining immune tolerance and suppressing immune responses. Their accumulation in the tumor microenvironment is a hallmark of many cancers, including colorectal cancer, and is strongly associated with poor prognosis [3, 4]. Tregs suppress the activity of effector T cells (e.g., CD8+ cytotoxic T cells) and other anti-tumor immune cells, thereby promoting tumor immune evasion and progression. The p ≤ 0.01 significance for Tregs highlights this as a robust and critical finding.
- [3] PubMed search for "regulatory T cells tumor microenvironment"
[4] GeneCards entry for FOXP3 (a key Treg marker)
- Trend for Higher Th2 cells in Adjacent Normal Tissue: Th2 cells are typically associated with type 2 immune responses, which are involved in allergic reactions and defense against helminths. While their role in cancer is complex and can be context-dependent, a relatively higher proportion in adjacent normal tissue (albeit with a marginal p-value) might suggest a difference in the baseline immune state or inflammatory response patterns between healthy and cancerous colon tissue. Some studies indicate that Th2 responses can promote tumor growth in certain contexts or indicate a shift away from Th1-mediated anti-tumor immunity.
- Higher "unassigned" cells in Adjacent Normal Tissue: The "unassigned" category refers to cells that could not be confidently classified into specific T cell subsets by the annotation pipeline. A higher proportion in adjacent normal tissue might indicate greater cellular heterogeneity or the presence of distinct T cell states in the non-tumorigenic environment that are not well-represented in the current reference annotations or are lost/altered in the tumor environment. Alternatively, it could also reflect differences in cell quality or processing between samples that are less likely, given the data context suggests robust annotation.
Overall, the data points to a substantial remodeling of the T cell compartment in colon tumors, with a clear enrichment of immunosuppressive (Tregs, ILCreg) and potentially pro-tumorigenic inflammatory (Th22) populations.
Clinical or Translational Implications
These findings have significant clinical and translational implications for colon cancer:
- Immunosuppressive Microenvironment: The marked increase in Tregs and ILCreg cells within the tumor microenvironment suggests a highly immunosuppressive environment. This could explain why some patients do not respond well to immunotherapies that rely on activating effector T cells.
- Therapeutic Targets: Targeting Tregs and ILCreg cells to deplete them or inhibit their suppressive function could be a viable strategy to enhance anti-tumor immunity and improve responses to existing immunotherapies, such as checkpoint inhibitors [5].
[5] PubMed search for "Treg depletion cancer therapy"
- Biomarker Potential: The proportions of Th22, ILCreg, and especially Treg cells could serve as prognostic biomarkers, with higher levels indicating a poorer prognosis due to increased immune suppression.
- Stratification of Patients: Understanding the differential T cell populations could help stratify patients for personalized treatment approaches, potentially identifying those who might benefit from Treg-targeting therapies in conjunction with other treatments.
- Complex Role of Th22: The increased Th22 population warrants further investigation to clarify its precise role in colon cancer progression and whether it represents a therapeutic target or a response to the tumor.
10. Macrophage (M1) Subset Proportion in Colon Tumor vs. Adjacent Normal Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportional abundance of the Macrophage (M1) subset population in colon tissue, comparing tumor samples against adjacent normal tissue samples. The boxplot visualization, generated using plot_box_for_celltype_population_with_signif_difference, highlights statistically significant differences in cell type proportions between these two conditions, based on a predefined p-value cutoff of 0.1.
Visual Summary
The boxplot displays the celltype proportion of Macrophage (M1) cells across "tumor" and "adjacent_normal" conditions.
- Condition Comparison: The proportion of Macrophage (M1) cells appears lower in the "adjacent_normal" condition compared to the "tumor" condition. The median proportion for "tumor" is approximately 61%, while for "adjacent_normal" it is around 53%.
- Statistical Significance: A p-value of 0.08 is indicated, suggesting a statistically significant difference between the two groups, as it is below the applied cutoff of 0.1.
- Distribution: Both groups show a distribution of proportions, with individual sample data points overlaid as black dots (stripplot). The interquartile range (IQR) for the "tumor" group is slightly wider than that for the "adjacent_normal" group, indicating more variability within the tumor samples.
Biological Interpretation
Macrophages are a critical component of the tumor microenvironment (TME) and play diverse roles in cancer progression. M1 macrophages are typically characterized by their pro-inflammatory and anti-tumorigenic functions. They are involved in pathogen clearance, antigen presentation, and secretion of inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), leading to cytotoxic effects against tumor cells [1].
The analysis shows that the proportion of M1 macrophages is significantly higher in tumor tissue compared to adjacent normal tissue (p=0.08). This observation is intriguing, as many studies report a shift towards M2-like (pro-tumor) macrophages in the TME, often associated with immune suppression and tumor growth [2]. However, the presence and activity of M1 macrophages in colorectal cancer (CRC) can vary depending on the specific tumor stage, location, and the overall immune context. A higher proportion of M1 macrophages in the tumor might suggest an ongoing inflammatory response attempting to contain the tumor, or it could reflect the complexity and heterogeneity of macrophage polarization within the TME, where different macrophage phenotypes coexist and interact [3].
The observation is consistent with the colon tissue context, where chronic inflammation is a known risk factor for CRC, and the immune landscape is often characterized by a dynamic interplay of various immune cell subsets.
Clinical or Translational Implications
The finding of a higher proportion of M1 macrophages in colon tumor tissue, while potentially indicative of an anti-tumor immune response, warrants further investigation into their functional state. If these M1 macrophages are indeed active and functional, they could contribute to a more favorable immune environment.
- Prognostic Marker: The proportion of M1 macrophages could serve as a potential prognostic biomarker for colon cancer, where higher proportions might correlate with better outcomes, though this requires validation.
- Immunotherapeutic Strategies: Understanding the factors that drive M1 macrophage infiltration and maintenance in colon tumors could open avenues for therapeutic interventions. Strategies aimed at enhancing M1 polarization or preventing their conversion to M2-like phenotypes might improve the efficacy of existing immunotherapies or lead to novel combination therapies for colorectal cancer [4].
References
- M1 Macrophage Function:
PubMed Search: "M1 macrophage function cancer"
- M2 Macrophages in TME:
PubMed Search: "M2 macrophages tumor microenvironment"
- Macrophages in Colorectal Cancer:
PubMed Search: "macrophage polarization colorectal cancer"
- Targeting Macrophages in Cancer Therapy:
PubMed Search: "macrophage targeting cancer therapy"
11. Ploidy Population Analysis of Intestinal Epithelial and Unassigned Cells in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of a combined population of Intestinal Epithelial cells and unassigned cells across various patient samples from both adjacent normal colon tissue and tumor tissue. The goal is to understand the chromosomal stability or instability within these cell types, particularly in the context of colorectal cancer. Intestinal Epithelial cells are identified as the tumor origin cell type, making their ploidy status especially relevant to malignancy.
Visual Summary
The stacked bar plots display the proportion of Aneuploid (maroon), Diploid (orange), and Unclear (light green) cells for each sample, separated by adjacent_normal and tumor conditions. Each bar represents a specific patient sample.
- Adjacent Normal Tissue:
- Many samples within the adjacent_normal group show a predominant diploid cell population (orange bars close to 100%).
- However, a subset of adjacent_normal samples (e.g., C152, C153, C066, C206, C011, C183) exhibit a noticeable proportion of aneuploid cells (maroon), ranging from approximately 20% to over 60% in some instances.
- The "Unclear" category (light green) represents a very small fraction across most adjacent normal samples.
- Tumor Tissue:
- In the tumor condition, there is a clear and generally higher prevalence of aneuploid cells compared to the adjacent_normal condition, particularly in the samples that also showed aneuploidy in the normal tissue (e.g., C152, C153, C066, C206).
- Several tumor samples (e.g., C152, C066, C206, C183) show a very high proportion of aneuploid cells, often exceeding 70-90% of the cell population.
- Similar to the adjacent_normal group, some tumor samples (e.g., C026, C015, C144, C071, C169, C218, C265, C003) still present as largely diploid, indicating inter-sample heterogeneity or specific tumor characteristics.
- The "Unclear" category remains minor in tumor samples.
Biological Interpretation
The observed ploidy patterns provide significant insights into the biology of colon cancer. Aneuploidy, the condition of having an abnormal number of chromosomes, is a well-established hallmark of cancer and is frequently associated with genetic instability in tumor cells [1].
- Elevated Aneuploidy in Tumors: The significantly increased proportion of aneuploid cells in the tumor samples, especially within the Intestinal Epithelial cell compartment (identified as the tumor origin cell type), strongly supports the malignant nature of these cells. This chromosomal instability drives tumor evolution, progression, and resistance to therapy [2].
- Aneuploidy in "Adjacent Normal" Tissue: The presence of aneuploid cells in some adjacent_normal samples is an intriguing finding. This could reflect several biological phenomena:
- Field Cancerization: The concept that apparently normal tissue surrounding a tumor may harbor pre-malignant changes or genetic alterations, including aneuploidy, due to exposure to similar carcinogenic factors [3].
- Microenvironmental Influence: Aneuploid stromal cells (if some are included in 'unassigned') or infiltrating immune cells could contribute, though less likely to be a high proportion.
- Sampling Variability/Contamination: Minor infiltration of tumor cells into the adjacent normal tissue biopsy or technical artifacts during sample processing cannot be entirely ruled out.
- Early Clonal Evolution: The presence of aneuploidy in adjacent normal samples could indicate early stages of clonal evolution towards malignancy, prior to overt tumor formation.
- Inter-sample Heterogeneity: The variation in aneuploidy levels among different tumor samples highlights the heterogeneity of colon cancer. Not all tumors exhibit the same degree of aneuploidy, and some may follow alternative pathways of genomic instability (e.g., microsatellite instability without extensive chromosomal changes). Additionally, the composition of the 'unassigned' category could vary, contributing to the overall ploidy profile of each sample.
Clinical or Translational Implications
The detection and quantification of aneuploidy can have several clinical implications:
- Biomarker for Malignancy: A high proportion of aneuploid Intestinal Epithelial cells is a strong indicator of malignancy and can aid in distinguishing tumor tissue from normal or benign lesions [4].
- Prognostic Indicator: The degree of aneuploidy has been explored as a prognostic marker in various cancers, with higher levels often correlating with aggressive disease and poorer outcomes [5].
- Therapeutic Targeting: Understanding the specific chromosomal alterations contributing to aneuploidy might open avenues for targeted therapies that exploit vulnerabilities associated with chromosomal instability, though this requires more detailed genomic analysis beyond ploidy status alone.
- Monitoring Field Cancerization: The presence of aneuploidy in adjacent normal tissue could potentially serve as an early risk marker for patients, guiding more intensive surveillance strategies.
References
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*, 144(5), 646-674. PubMed Search: Hallmarks of Cancer Aneuploidy
- Davoli, T., & de Lange, T. (2018). The Causes and Consequences of Aneuploidy in Cancer. *Annual Review of Cancer Biology*, 2, 297-313. PubMed Search: Aneuploidy Cancer Consequences
- Rubio, C. A. (2010). Field cancerization in the colon and rectum. *World Journal of Gastroenterology: WJG*, 16(29), 3624. PubMed Search: Field cancerization colon
- Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instability in colorectal cancers. *Nature*, 396(6712), 643-649. PubMed Search: Colorectal cancer aneuploidy biomarker
- Maley, C. C., et al. (2006). Aneuploidy and the evolution of cancer. *Evolution*, 60(9), 1709-1721. PubMed Search: Aneuploidy cancer prognosis
12. Colon Cancer Cell-Cell Interaction Landscape: Tumor vs. Adjacent Normal
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB results, comparing tumor and adjacent normal conditions within colorectal tissue. The focus is on interactions involving key cell types: Intestinal Epithelial cells (as tumor-origin cells), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+). The dot plots visualize up to 80 most significant interactions per condition, indicating the strength (log2(mean) expression) and significance (-log10(p-value)) of ligand-receptor pairs between cell types.
Visual Summary
The two dot plots display distinct yet overlapping cell-cell interaction patterns in adjacent normal versus tumor conditions.
- Adjacent Normal (Top Plot): Shows a moderate density of interactions, particularly between "Diploid Intestinal Epi" and immune cells (Macrophages, T cells CD4+, T cells CD8+), and within Macrophages. Key interactions include CXCL12-CXCR4, SPP1-integrin, TGFB1-TGFBR1_TGFBR2, and APOE-TREM2_CALM1_CD33.
- Tumor (Bottom Plot): Presents a seemingly denser and often stronger (indicated by more prominent yellow/green dots) interaction landscape. While many interactions observed in adjacent normal persist, several new or significantly enhanced interactions emerge. Notably, there are increased epithelial-epithelial (Diploid Intestinal Epi to Diploid Intestinal Epi) interactions involving Ephrin-Eph receptors, and a marked increase in T cell (CD4+ to CD4+) regulatory interactions (CD80/86 with CD28/CTLA4). Interactions involving Macrophages remain strong, with some new prominent partners like MIF-CD74_CD44.
- Cell Type Representation: On the y-axis, "Diploid Intestinal Epi" is used for epithelial cells, paired with various immune cells (Macrophage, T cell CD4+, T cell CD8+) and itself. While Fibroblasts were specified as target cells, no fibroblast-mediated interactions were among the top 80 shown in either condition. This indicates their interactions might be less significant or less frequent than those highlighted, or involve different partners not prioritized.
Biological Interpretation
The observed differences in CCI patterns between tumor and adjacent normal tissue provide insights into the altered cellular communication driving colorectal cancer progression.
- Persistent Epithelial-Immune Communication:
- The CXCL12-CXCR4 axis shows consistently strong and significant interactions across both conditions, particularly from "Diploid Intestinal Epi" to Macrophages and T cells. This pathway is crucial for immune cell trafficking and, in cancer, plays a key role in tumor growth, angiogenesis, and immune evasion by recruiting pro-tumorigenic cells. PubMed search: CXCL12 CXCR4 cancer
- SPP1-integrin_aVb1_complex interactions (Macrophage to "Diploid Intestinal Epi") and TGFB1-TGFBR1_TGFBR2 interactions (Macrophage to Macrophage and "Diploid Intestinal Epi") are also robust in both conditions, often appearing stronger in the tumor. SPP1 (Osteopontin) promotes tumor progression and metastasis, while TGF-β signaling from macrophages contributes to immune suppression and fibrosis in the tumor microenvironment (TME). GeneCards: SPP1
- Tumor-Specific Epithelial Remodeling and Signaling:
- A notable enrichment of Ephrin-Eph receptor interactions (e.g., EFNB2-EPHB4, EFNB1-EPHB2, EFNA1-EPHA2, EFNA4-EPHA4) is observed within "Diploid Intestinal Epi" cells in the tumor. Ephrin-Eph signaling is critical for cell adhesion, migration, and tissue organization, and its dysregulation in cancer promotes tumor cell proliferation, invasion, and angiogenesis. This suggests significant self-organizing or proliferative activity within the tumor epithelial compartment. PubMed search: Ephrin Eph receptor cancer progression
- The term "Diploid Intestinal Epi" in the tumor context, given the expand_ploidy_from_tumor_origin parameter, refers to the epithelial cell compartment. While aneuploid cells are the hallmark of many cancers, this specific labeling suggests that either the detected tumor epithelial cells predominantly maintained a diploid status in these key interactions, or the analysis captured interactions involving tumor-associated diploid epithelial cells that contribute to the tumor microenvironment.
- Complex Immune Modulation in the TME:
- The tumor microenvironment displays a striking increase in T cell costimulatory and coinhibitory interactions (e.g., CD80/86 with CD28/CTLA4) within CD4+ T cells. This indicates an active but often dysregulated T cell response, where both activation and suppression signals are highly engaged. The presence of CTLA4-mediated interactions suggests mechanisms of immune checkpoint regulation are robustly active, likely contributing to T cell exhaustion and immune evasion. UniProt: CTLA4
- MIF-CD74_CD44 interactions (from "Diploid Intestinal Epi" to Macrophages and T cells CD4+) are more prominent in the tumor. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine frequently overexpressed in cancer, promoting tumor growth, angiogenesis, and immune evasion. Its increased activity highlights a heightened inflammatory and pro-tumorigenic state. GeneCards: MIF
Clinical or Translational Implications
The identified cell-cell interaction changes present several avenues for therapeutic intervention and biomarker discovery in colorectal cancer:
- Targeting the CXCL12-CXCR4 Axis: Given its consistent and strong presence in both conditions and its known role in cancer progression and immune evasion, blocking CXCR4 or CXCL12 could hinder tumor growth, metastasis, and the recruitment of immunosuppressive cells.
- Modulating SPP1 and TGF-β Signaling: The strong and potentially enhanced SPP1 and TGF-β pathways in the tumor highlight their importance in creating a pro-tumorigenic and immunosuppressive TME. Therapies targeting these pathways could disrupt tumor growth, reduce fibrosis, and enhance anti-tumor immunity.
- Ephrin-Eph Receptors as Novel Targets: The increased Ephrin-Eph interactions within tumor epithelial cells suggest a vulnerability that could be exploited. Therapeutic strategies aimed at disrupting these interactions could inhibit tumor cell proliferation, migration, and invasion, potentially preventing metastatic spread.
- Enhancing or Restoring T cell Function: The prominent CD80/86-CD28/CTLA4 interactions underscore the complex immune regulation in the TME. While immune checkpoint blockade targeting CTLA4 is an established therapy, further understanding and modulating the balance of these costimulatory and coinhibitory signals could lead to more effective T cell-based immunotherapies.
- Interfering with MIF-CD74_CD44 Signaling: The heightened MIF activity in the tumor points to its potential as a therapeutic target. Inhibitors of MIF or its receptors could dampen the pro-inflammatory and pro-tumorigenic environment, thereby slowing cancer progression.
- Fibroblast Involvement: The absence of fibroblast interactions among the top 80 pairs does not negate their role in the TME but suggests that, for the selected cell types and interaction thresholds, their direct ligand-receptor interactions might be less dominant than those shown. Further investigation into specific fibroblast interactions or their secreted factors could still be warranted.
13. Adjacent Normal 및 종양 조직의 세포-세포 상호작용 분석
[Analysis Visualization Results]...
Analysis Overview
본 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 활용하여 대장 조직의 인접 정상(adjacent_normal) 및 종양(tumor) 조건에서 세포 간 상호작용(Cell-Cell Interaction, CCI)을 규명하는 것을 목표로 합니다. CellPhoneDB를 사용하여 리간드-수용체 쌍의 상호작용 강도(mean expression)와 통계적 유의성(p-value)을 평가했으며, 각 조건에서 상위 80개 상호작용을 시각화하였습니다. 이러한 상호작용 패턴을 비교함으로써 종양 미세환경(Tumor Microenvironment, TME) 특유의 생물학적 기전을 이해하고 잠재적인 치료 표적을 식별하고자 합니다.
Visual Summary
두 조건에 대한 점 도표(dot plot)는 세포 유형 쌍(y축)과 리간드-수용체(L-R) 쌍(x축) 간의 상호작용을 시각화합니다. 점의 크기는 상호작용의 p-value(-log10 변환)를 나타내며, 큰 점은 높은 통계적 유의성을 의미합니다. 점의 색상은 상호작용의 평균 발현 강도(log2 변환)를 나타내며, 녹색/노란색 계열은 강한 상호작용을, 보라색 계열은 약한 상호작용을 나타냅니다.
Adjacent Normal 조건 (상단 그림):
- Diploid Intestinal Epi(정상 상피세포)와 다양한 면역 세포(T cell CD4+, T cell CD8+, Macrophage 등) 및 다른 상피세포 간의 상호작용이 관찰됩니다.
- Macrophage와 Diploid Intestinal Epi 간의 SPP1-integrin 및 TGFB1-TGFBR1/2 상호작용이 두드러집니다.
- Plasma cell과 B cell 간의 CD40LG-CD40 상호작용도 나타납니다.
- 전반적으로 다양한 세포 유형 간의 기저 상호작용이 나타나며, 면역 감시 및 조직 항상성에 중요한 역할을 하는 것으로 보입니다.
Tumor 조건 (하단 그림):
- Intestinal Epi(종양 상피세포, 종양 기원 세포 유형)와 면역 세포(T cell, Macrophage, Plasma cell) 및 다른 세포 유형 간의 상호작용이 인접 정상 조직보다 전반적으로 더 강하고 다양하게 나타나는 경향이 있습니다.
- 특히 Macrophage와 Intestinal Epi 사이의 MIF-CD74_CXCR4_CD44 및 SPP1-CD44_integrin 상호작용이 매우 강력하고 유의하게 나타납니다.
- T cell CD4+/CD8+와 Intestinal Epi 간의 CXCL12-CXCR4 상호작용이 종양에서 두드러지게 관찰됩니다.
- Plasma cell과 B cell 간의 TNFSF13-TNFRSF13C (BAFF-BAFFR) 상호작용이 종양에서 매우 강력하게 나타나, B 세포 생존 및 활성 증가를 시사합니다.
- VEGFA-KDR/FLT1 상호작용은 Intestinal Epi와 Macrophage에서 모두 나타나며, 종양 내 혈관신생 가능성을 시사합니다.
- TGFB1-TGFBR1/2 상호작용은 인접 정상 조직보다 종양 조직에서 더 광범위하고 강력하게 나타나, 면역 억제 환경의 강화를 의미합니다.
Biological Interpretation
종양 미세환경은 복잡한 세포-세포 상호작용을 통해 암세포의 성장, 침윤, 전이 및 면역 회피를 지원합니다. 본 분석 결과는 이러한 종양 특이적 상호작용의 중요한 측면을 밝혀냅니다.
- 면역 억제 및 염증 신호:
- TGFB1-TGFBR1/2: Macrophage와 Intestinal Epi를 포함한 다양한 세포 유형 간의 TGFB1 신호전달은 종양 미세환경에서 중요한 면역 억제 경로입니다. TGF-$\beta$는 T 세포 활성 억제, 조절 T 세포(Treg) 분화 유도, 섬유아세포 활성화 등 다양한 종양 촉진 효과를 가집니다 PubMed search: TGFB1 cancer immunosuppression. 종양 조직에서 이 상호작용의 강화는 강력한 면역 억제 환경을 시사합니다.
- MIF-CD74_CXCR4_CD44: Macrophage와 Intestinal Epi 사이의 MIF(Macrophage Migration Inhibitory Factor) 신호는 종양에서 매우 강력합니다. MIF는 염증, 면역 반응 조절, 세포 증식, 혈관신생 및 전이에 관여하는 사이토카인으로, 암 진행에 중요한 역할을 합니다 GeneCards: MIF.
- SPP1-CD44_integrin: Macrophage와 Intestinal Epi 간의 SPP1(Osteopontin) 상호작용도 종양에서 강화됩니다. SPP1은 세포 접착, 이동, 침윤, 혈관신생 및 면역 조절에 관여하며, 많은 암종에서 불량한 예후와 관련이 있습니다 GeneCards: SPP1.
- 종양 상피세포-면역 세포 상호작용:
- CXCL12-CXCR4: T cell CD4+/CD8+와 Intestinal Epi 간의 CXCL12-CXCR4 축의 강화는 종양 미세환경에서 T 세포의 이동 및 모집에 영향을 미치며, 암세포의 생존, 증식 및 전이를 촉진하는 것으로 알려져 있습니다 PubMed search: CXCL12 CXCR4 cancer.
- ICAM1_integrin_aL_b2: Macrophage와 T cell CD4+/CD8+ 사이의 ICAM1-integrin 상호작용은 면역 세포 간의 접착 및 상호작용을 매개하여 면역 반응에 영향을 미칩니다.
- 혈관신생 및 기질 재형성:
- VEGFA-KDR/FLT1: Intestinal Epi 및 Macrophage에서 관찰되는 VEGFA-VEGFR(KDR/FLT1) 신호는 혈관신생을 강력하게 유도하며, 종양 성장에 필수적인 산소와 영양분 공급을 촉진합니다 GeneCards: VEGFA. 종양 조직에서의 활성화는 종양 혈관신생 증가를 시사합니다.
- LAMA3_integrin: Intestinal Epi 세포 간의 라미닌-인테그린 상호작용은 세포 접착 및 기저막 구성에 중요하며, 종양에서 기질 재형성과 관련될 수 있습니다.
- B 세포 및 형질 세포 활성:
- TNFSF13-TNFRSF13C: Plasma cell과 B cell 간의 TNFSF13 (BAFF)와 TNFRSF13C (BAFFR) 상호작용이 종양에서 매우 강력하게 나타납니다. BAFF-BAFFR 축은 B 세포의 생존, 성숙, 증식 및 항체 생산을 조절하며, 일부 암종에서는 B 세포 반응의 활성화 및 종양 진행과 연관될 수 있습니다 GeneCards: TNFSF13.
Diploid Intestinal Epi (인접 정상)와 Intestinal Epi (종양) 간의 명확한 구분은 종양 상피세포가 주변 미세환경과의 상호작용 패턴을 변화시켜 종양 성장을 촉진하고 면역 반응을 회피하는 메커니즘을 강조합니다.
Clinical or Translational Implications
본 CCI 분석 결과는 대장암의 진단, 예후 예측 및 치료 전략 개발에 중요한 통찰력을 제공합니다.
- 치료 표적 발굴:
- 종양 미세환경에서 특이적으로 강화된 MIF-CD74_CXCR4_CD44, SPP1-CD44_integrin, CXCL12-CXCR4, VEGFA-KDR/FLT1, TGFB1-TGFBR1/2, TNFSF13-TNFRSF13C 등의 L-R 축은 유망한 치료 표적이 될 수 있습니다. 이들 리간드 또는 수용체를 억제하는 약물 개발(예: 항체 치료제, 소분자 억제제)은 암세포 성장 억제, 면역 반응 회복, 혈관신생 저해 등의 효과를 가져올 수 있습니다. 예를 들어, TGF-$\beta$ 억제제는 임상 시험에서 면역항암제와 병용하여 효과를 보이고 있으며 PubMed search: TGFB inhibitor cancer clinical trial, CXCR4 억제제도 전이성 암 치료에서 연구되고 있습니다 PubMed search: CXCR4 inhibitor cancer clinical trial.
- 바이오마커 개발:
- 종양 특이적으로 높은 발현과 강력한 상호작용을 보이는 L-R 쌍은 대장암의 진단 및 예후 예측을 위한 바이오마커로 활용될 가능성이 있습니다. 예를 들어, 종양 내 특정 세포 유형에서 SPP1, MIF, CXCL12, VEGFA 또는 TNFRSF13C의 발현 수준은 종양의 진행 정도나 치료 반응을 예측하는 데 사용될 수 있습니다.
- 병용 치료 전략:
- TGF-$\beta$ 신호 경로 활성화는 면역 체크포인트 억제제(ICI)에 대한 반응성을 감소시키는 것으로 알려져 있습니다. 따라서 TGF-$\beta$ 억제제를 ICI와 병용하는 전략은 면역 회피를 극복하고 대장암 환자의 치료 반응을 개선할 수 있습니다. 유사하게, 혈관신생 억제제(anti-VEGFA)를 다른 치료제와 병용하는 전략도 고려될 수 있습니다.
- 실험적 검증 및 임상 연구:
- 본 분석에서 도출된 핵심 L-R 상호작용은 *in vitro* (예: 공동 배양 모델), *in vivo* (예: 환자 유래 오가노이드, 동물 모델) 환경에서 기능적 검증이 필요합니다. 이를 통해 각 상호작용이 종양 생물학 및 면역 반응에 미치는 인과적 영향을 규명하고, 특정 L-R 쌍을 표적으로 하는 치료제의 임상적 유효성을 평가하는 후속 연구의 기반을 마련할 수 있습니다.
본 결과는 대장암 종양 미세환경의 복잡한 통신 네트워크를 해독하고, 새로운 치료 전략을 개발하기 위한 핵심적인 분자 경로를 제시합니다.
14. Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigated cell-cell interactions (CCI) involving a curated set of immune checkpoint and cell cycle-related genes across "adjacent_normal" and "tumor" conditions in single-cell RNA-seq data from Colon tissue. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between different cell types, focusing on the expression levels (mean) and statistical significance (p-value) of these interactions. The parameter expand_ploidy_from_tumor_origin: True allowed for distinctions based on ploidy status, specifically highlighting "Diploid Intestinal Epithelial" cells, which represent normal-like epithelial cells in the tissue microenvironment.
Visual Summary
Adjacent Normal Tissue
The dot plot for adjacent normal tissue shows several significant cell-cell interactions, primarily involving T cells (CD8+, CD4+) and Macrophages, with some interaction between Macrophages and Diploid Intestinal Epithelial cells.
- Immune Co-stimulation/Signaling: Notable interactions include CD86 CD28 between T CD8+|T CD8+ cells, suggesting T cell co-stimulation. IFNG Type_II_IFNR interactions are prominent between T CD8+|T CD8+ and T CD8+|Mac (Macrophages), indicating active IFN-gamma signaling within the immune compartment.
- Macrophage-Epithelial Interaction: A strong interaction observed is TGFB1 TGFbeta_receptor1 between Mac|Diploid Intestinal Epi cells, alongside TGFB1_integrin_avb6_complex, suggesting active TGF-β signaling between macrophages and normal-like epithelial cells.
Tumor Tissue
The tumor tissue dot plot reveals significant changes and new interactions compared to the adjacent normal tissue, particularly in immune checkpoint and growth factor pathways.
- Emergence of Immune Checkpoint Interactions: A prominent and strong interaction observed is CD274 CD80 between Mac|T CD4+ cells. This indicates PD-L1 (CD274) on macrophages interacting with CD80 on CD4+ T cells, a known non-canonical immune inhibitory axis. PubMed search: PD-L1 CD80 interaction T cells immune suppression
- Increased Growth Factor Signaling: New interactions involving EGF-family ligands and EGFR appear in the tumor. Specifically, EREG EGFR and HBEGF EGFR interactions are observed between Mac|T CD4+ cells, suggesting macrophage-derived growth factor support for CD4+ T cells in the tumor microenvironment. GeneCards: EREG, GeneCards: HBEGF
- Altered Co-stimulatory Interactions: While CD86 CD28 was seen in normal T cells, in the tumor, CD80 CD28 appears as a strong interaction between Mac|T CD4+ cells. Additionally, CD80 CD86 interaction is observed between Mac|Mac cells.
- Sustained TGF-β Signaling: The strong TGFB1 TGFbeta_receptor1 interaction between Mac|Diploid Intestinal Epi cells persists and appears to be one of the strongest interactions in the tumor microenvironment as well, suggesting ongoing TGF-β mediated processes. The TGFB1_integrin_avb6_complex also remains. PubMed search: integrin avb6 TGFB1 activation cancer
- IFN-gamma Signaling: IFNG Type_II_IFNR interactions between T cells and macrophages continue to be present, indicating persistent, though potentially altered, type II interferon responses.
Biological Interpretation
Altered Immune Checkpoint Landscape in Tumor
The most striking difference is the emergence of the CD274 (PD-L1)-CD80 interaction in the tumor, specifically between macrophages and CD4+ T cells. CD274 (PD-L1) is a critical immune checkpoint protein often expressed by tumor cells and immune cells (like macrophages) to suppress T cell activity by binding to PD-1 on T cells. However, its interaction with CD80 (B7-1) on T cells is also described to inhibit T cell activation, leading to immune evasion. This highlights a potentially active immunosuppressive mechanism orchestrated by macrophages in the colorectal tumor microenvironment. The presence of CD80-CD28 interactions (co-stimulation) alongside CD274-CD80 (inhibition) on the same cell types (Mac|T CD4+) indicates a complex balance of activating and inhibitory signals impacting T cell function.
Growth Factor Signaling in the Tumor Microenvironment
The appearance of EREG EGFR and HBEGF EGFR interactions in the tumor (Mac|T CD4+) suggests that macrophages in the tumor microenvironment might be releasing epidermal growth factor (EGF)-like ligands that can engage EGFR on CD4+ T cells. EGFR signaling is well-known for its role in cell proliferation, survival, and migration, and its activation on T cells could influence their differentiation, survival, or effector function in ways that might be detrimental to anti-tumor immunity.
Sustained Immunosuppressive TGF-β Signaling
The robust TGFB1-TGFbeta_receptor1 signaling between macrophages and Diploid Intestinal Epithelial cells in both adjacent normal and, particularly, in tumor tissue, underscores the significance of TGF-β in colorectal cancer. TGF-β is a potent immunosuppressive cytokine that can inhibit T cell proliferation and function, promote regulatory T cell development, and foster an immunosuppressive microenvironment. The interaction with integrin_avb6_complex further suggests activation of latent TGF-β, amplifying its effects on epithelial cells and the surrounding stroma, contributing to fibrosis and tumor progression. The involvement of "Diploid Intestinal Epithelial" cells implies that even normal-like epithelial cells in the tumor context are subject to significant pro-tumorigenic signaling from macrophages.
Absence of Direct Cell Cycle Gene Interactions
While many cell cycle-related genes were included in the query, the plot_cci_dots results exclusively show ligand-receptor interactions related to immune and growth factor signaling. This is expected, as most cell cycle genes encode intracellular proteins (e.g., CDKs, cyclins, E2Fs, MCMs, TP53) that do not participate in direct cell-cell ligand-receptor binding at the cell surface. Their roles are primarily within the cell, regulating progression through the cell cycle. Therefore, the absence of these genes in CCI plots is not a negative finding but rather a confirmation that CellPhoneDB, which focuses on extracellular ligand-receptor pairs, is correctly identifying cell surface interactions.
Clinical or Translational Implications
The findings highlight several potential therapeutic targets and mechanisms for modulating the immune response in colorectal cancer:
- Immune Checkpoint Blockade: The prominent CD274 (PD-L1)-CD80 interaction between macrophages and CD4+ T cells in the tumor suggests that therapies targeting this non-canonical immune checkpoint axis, in addition to the classic PD-1/PD-L1 pathway, could be beneficial. Further investigation into the functional consequences of this specific interaction on T cell subsets could inform novel immunotherapeutic strategies.
- EGFR Inhibition: The emergence of EREG/HBEGF-EGFR signaling from macrophages to CD4+ T cells in the tumor microenvironment suggests that targeting EGFR could not only impact tumor cell proliferation (if aneuploid epithelial cells also express EGFR) but also modulate immune cell function. This dual effect could be leveraged in combination therapies.
- TGF-β Pathway Inhibition: The sustained and strong TGF-β signaling in the tumor microenvironment, particularly between macrophages and epithelial cells, reinforces TGF-β as a critical driver of immunosuppression and tumor progression. Therapeutic approaches that block TGF-β signaling, or specifically target integrin αvβ6 to prevent TGF-β activation, could help overcome immune resistance and reduce desmoplasia in colorectal cancer. PubMed search: TGF-beta inhibitors cancer therapy
These insights provide a detailed understanding of the dynamic interplay between immune cells and epithelial cells in colorectal cancer, offering potential avenues for targeted therapeutic interventions aimed at reprogramming the tumor microenvironment.
15. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies statistically significant differences in cell-cell interactions (CCIs) between adjacent normal colon tissue and tumor tissue. The dot plot visualizes these differences, highlighting CCIs that are predominantly active in one condition over the other. The interactions primarily involve major immune cells (T cells, B cells, Myeloid cells, Mast cells, ILC), stromal cells (Fibroblasts, Endothelial cells), and Intestinal Epithelial cells (specifically Enterocyte Epithelial cells, or "Ent.Epi"), with some interactions further refined by the inferred ploidy status (Diploid or Aneuploid) of the epithelial cells. The dot size represents the statistical significance (-log10(p-value) of difference between conditions), while the color intensity indicates the standardized mean interaction strength within each sample.
Visual Summary
The dot plot clearly delineates two major groups of cell-cell interactions: those preferentially active in adjacent normal tissue (left half of the plot, marked by the vertical blue line) and those predominantly found in tumor tissue (right half). Similarly, samples are grouped by condition (adjacent normal vs. tumor) on the y-axis, separated by a horizontal blue line.
Key visual observations include:
- Condition-Specific Clustering: A striking pattern emerges where specific CCIs are strongly active (dark red, large dots) almost exclusively within either the adjacent normal samples or the tumor samples, demonstrating clear condition-specific interaction landscapes.
- Adjacent Normal Dominant Interactions: The left block of the plot shows numerous dark red, large dots concentrated within the 'adjacent_normal' samples. These interactions appear less active or non-significant in 'tumor' samples. Many of these interactions involve Ent.Epi(Diploid), suggesting their role in maintaining normal tissue homeostasis.
- Tumor Dominant Interactions: The right block, conversely, displays a high density of dark red, large dots within the 'tumor' samples. These interactions are largely absent or very weak in 'adjacent_normal' samples. Notably, a significant proportion of these tumor-specific interactions involve Ent.Epi(Aneuploid), indicative of transformed epithelial cells.
- Cell Type Enrichment: Endothelial cells (Endo), Fibroblasts (Fib), and Aneuploid Enterocyte Epithelial cells (Ent.Epi(Aneuploid)) are frequently observed in the highly active tumor-specific interactions.
- Sample Heterogeneity: While clear condition-specific patterns exist, some variability in interaction strength is observed among individual samples within both the adjacent normal and tumor groups, reflecting inter-patient biological diversity.
Biological Interpretation
The distinct CCI patterns reveal fundamental differences in cellular communication between healthy and cancerous colon microenvironments.
Interactions Predominant in Adjacent Normal Tissue:
These interactions likely contribute to maintaining tissue homeostasis, immune surveillance, and normal epithelial function.
- Immune-Epithelial Crosstalk: Interactions like FCER2_FGFR2--B cell|Ent.Epi(Diploid) and IL7_IL7_receptor--Ent.Epi(Diploid)|T cell CD4+ point to active communication between immune cells and diploid epithelial cells, crucial for local immunity and tissue repair in the normal colon. FCER2 (CD23) on B cells is involved in IgE regulation, while IL-7 is vital for T cell development and survival.
- Myeloid Cell Regulation: The Dehydroepiandrosterone--Endo|Mac and CLU_TREM2_receptor--Ent.Epi(Aneuploid)|Mac interactions suggest roles for macrophages and endothelial cells, potentially in modulating inflammation or tissue remodeling, even involving some aneuploid epithelial cells in the context of normal tissue, perhaps indicating early changes or a surveillance mechanism. TREM2 on macrophages plays roles in phagocytosis and inflammation GeneCards: TREM2.
- Stromal-Epithelial Interactions: THBS1_CD36--Ent.Epi(Diploid)|Endo highlights the interaction between thrombospondin-1 (THBS1, an anti-angiogenic and immune-regulatory protein) and CD36 on endothelial and diploid epithelial cells, which could be important for regulating blood vessel integrity and epithelial health.
Interactions Predominant in Tumor Tissue:
These interactions underscore the profound reorganization of the tumor microenvironment, promoting tumor growth, angiogenesis, and immune evasion.
- Extracellular Matrix (ECM) Remodeling and Adhesion: A striking number of strong interactions involve collagen (COL4A1, COL5A1), laminin (LAMC1), and various integrin complexes (e.g., COL4A1_integrin_a1b1_complex--Endo|Ent.Epi(Aneuploid), LAMC1_integrin_a6b1_complex--Endo|Ent.Epi(Aneuploid), COL5A1_integrin_a1b1_complex--Endo|Fibroblast). This signifies extensive ECM remodeling, altered cell-matrix adhesion, and enhanced cell migration and invasion, critical processes in cancer progression. Integrins are key receptors for ECM components, mediating cell adhesion, migration, and signaling PubMed search: integrins cancer ECM remodeling.
Angiogenesis and Stromal Activation:
- PDGFD_PDGFRB--Endo|Fibroblast points to active platelet-derived growth factor (PDGF) signaling, a crucial driver of angiogenesis, fibroblast activation, and stromal remodeling in tumors PubMed search: PDGFD PDGFRB cancer angiogenesis.
- JAG2_NOTCH3--Endo|Endo and DLL4_NOTCH3--Endo|Endo highlight Notch signaling within endothelial cells, which is essential for sprouting angiogenesis and vascular development within the tumor microenvironment PubMed search: DLL4 NOTCH3 angiogenesis cancer.
- PGF_NRP2--Fibroblast|Endo involves placental growth factor (PGF) and Neuropilin-2 (NRP2), a well-established axis promoting angiogenesis and lymphangiogenesis in cancer GeneCards: PGF, GeneCards: NRP2.
- Immune Modulation: CD96_NECTIN1--T cell CD4+|Ent.Epi(Aneuploid) suggests altered immune interactions involving CD96, an immune checkpoint molecule, on T cells. This interaction could contribute to immune evasion by modulating T cell function in the presence of aneuploid tumor cells GeneCards: CD96.
- Ploidy-Specific Interactions: The frequent involvement of Ent.Epi(Aneuploid) in tumor-specific interactions, compared to Ent.Epi(Diploid) in normal-specific ones, strongly suggests that the genetic instability and resulting altered cellular phenotypes of aneuploid tumor cells fundamentally rewire their communication networks within the tumor microenvironment.
Clinical or Translational Implications
The identified condition-specific cell-cell interactions offer valuable insights with potential clinical and translational implications for colorectal cancer.
- Biomarker Discovery: The distinct panels of CCIs could serve as diagnostic or prognostic biomarkers. For instance, high activity of ECM-related integrin signaling (e.g., COL4A1/LAMC1-integrin complexes) or angiogenic pathways (PDGFD-PDGFRB, PGF-NRP2, Notch signaling) could indicate tumor presence or aggressive disease.
- Therapeutic Targets: The highly active tumor-specific interactions represent promising targets for therapeutic intervention. Inhibiting critical axes like PDGF/PDGFR, Notch, or PGF/NRP2 signaling could disrupt tumor angiogenesis and stromal support. Targeting specific integrin interactions might reduce tumor cell invasion and metastasis.
- Understanding Immune Evasion: The CD96_NECTIN1 interaction highlights a potential immune checkpoint pathway active in the tumor, offering avenues for immunotherapeutic strategies.
- Personalized Medicine: The observed sample heterogeneity suggests that a "one-size-fits-all" approach to targeting CCIs might be suboptimal. Stratifying patients based on their specific CCI profiles could enable more personalized treatment strategies.
- Insights into Tumor Progression: The involvement of aneuploid epithelial cells in tumor-specific interactions underscores the importance of genomic instability in shaping the tumor microenvironment and driving disease progression. Future studies could explore how these altered interactions contribute to malignancy and resistance to therapy.
16. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify condition-specific surfaceome markers in Intestinal Epithelial cells from colon tissue, comparing tumor and adjacent normal conditions. A dot plot visualization displays the expression patterns of up to 50 surface-localized genes across individual samples. The y-axis groups samples by their inferred ploidy status (Diploid vs. non-Diploid/Aneuploid) and implicitly by their tissue origin (adjacent normal vs. tumor). The dot size represents the fraction of cells expressing a given gene within each sample group, while the color intensity reflects the mean expression level.
Visual Summary
The dot plot clearly delineates two distinct clusters of Intestinal Epithelial cell samples based on their surfaceome marker expression:
- Upper Cluster (Diploid Samples): This group comprises samples labeled "Diploid CXXX" (e.g., Diploid C172, Diploid C168). These samples generally exhibit very low mean expression (lighter colors) and a low fraction of cells expressing (smaller dot sizes) most of the listed surfaceome markers. This pattern is highly suggestive of Intestinal Epithelial cells derived from adjacent normal tissue.
- Lower Cluster (Non-Diploid/Tumor Samples): This group includes samples labeled "CXXX" (e.g., C161, C165, C166). These samples show a striking upregulation of a large panel of surfaceome markers, characterized by high mean expression (darker red colors) and a high fraction of cells expressing these genes (larger dot sizes). Given the data context (ploidy_dec and conditions), these samples most likely represent aneuploid Intestinal Epithelial cells from tumor tissue.
The overall pattern indicates a strong differential expression of specific surface proteins in tumor-associated Intestinal Epithelial cells compared to their normal counterparts.
Biological Interpretation
The analysis successfully identified a panel of surfaceome markers that are highly and selectively upregulated in tumor-derived Intestinal Epithelial cells. These markers represent significant changes in the cell surface proteome during colon tumorigenesis, impacting cell-cell communication, adhesion, metabolism, and signaling pathways.
Key Tumor-Associated Surfaceome Markers:
A prominent set of genes shows marked upregulation in the tumor-associated (lower) cluster:
- MET (MET proto-oncogene, receptor tyrosine kinase): MET is a well-established oncogene whose activation drives cell proliferation, survival, migration, and invasion in various cancers, including colorectal cancer. Its strong upregulation here highlights its potential role in tumor progression in this cohort. PubMed search: MET receptor tyrosine kinase cancer therapy
- PMEPA1 (Prostate transmembrane protein, androgen induced 1): Often dysregulated in cancer, PMEPA1 can modulate TGF-β signaling, which plays a complex and context-dependent role in tumor development, from tumor suppression to promotion. GeneCards: PMEPA1
- RNF43 (Ring finger protein 43): RNF43 is a negative regulator of the Wnt signaling pathway, crucial for intestinal homeostasis. Mutations or altered expression of RNF43 are frequently observed in colorectal cancer, leading to constitutive Wnt pathway activation and promoting tumor growth. GeneCards: RNF43
- ITGA2 (Integrin alpha 2): Integrins are cell surface receptors involved in cell-extracellular matrix adhesion and signaling. ITGA2 can mediate interactions with collagen and other matrix components, influencing cell migration, invasion, and tumor metastasis. GeneCards: ITGA2
- SLC Family Genes (Solute Carrier proteins): Several solute carrier family members, including *SLC52A2*, *SLC1A5*, *SLC3A2*, and *SLC7A1*, are highly expressed. These proteins transport a wide range of substrates, including amino acids, vitamins, and ions, and their dysregulation is a common feature of cancer cells to support their increased metabolic demands and rapid proliferation. PubMed search: Solute carrier proteins cancer metabolism
- TSPAN6 (Tetraspanin 6): Tetraspanins are membrane proteins that form complexes with other proteins, influencing cell adhesion, motility, proliferation, and invasion, and are often implicated in cancer progression. GeneCards: TSPAN6
- Other significantly upregulated markers include *PIGT*, *SERINC3*, *LAMP2*, *SERINC5*, *LTBR*, *TM4SF1*, *M6PR*, *EFNA1*, *F11R*, *TMEM63A*, *UBAC2*, *ANKH*, *RNF130*, *TM9SF4*, *TMEM9*, *PTPRA*, and *EFNB1*. This broad panel of surface proteins suggests extensive remodeling of the cell surface landscape in malignant Intestinal Epithelial cells, affecting diverse cellular functions critical for cancer development and maintenance.
Clinical or Translational Implications
The identified tumor-specific surfaceome markers hold significant clinical and translational potential:
- Diagnostic and Prognostic Biomarkers: Genes like *MET*, *PMEPA1*, *RNF43*, and *ITGA2*, with their distinct upregulation in tumor Intestinal Epithelial cells, could serve as valuable diagnostic biomarkers to differentiate tumor from normal tissue. Their surface localization makes them excellent candidates for detection via immunohistochemistry on tissue biopsies or advanced imaging techniques. They may also hold prognostic value, with high expression potentially correlating with disease aggressiveness or patient outcome, though this requires further investigation.
- Therapeutic Targets: The surfaceome markers, particularly those with known functional roles in cancer (e.g., *MET*), represent promising therapeutic targets.
- MET is already a target for specific kinase inhibitors in other cancers, suggesting its potential as a drug target in colon cancer.
- Other highly expressed surface proteins could be explored for the development of novel targeted therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, or CAR-T cell therapies. Such therapies, designed to specifically target tumor cell surface antigens, could offer improved efficacy and reduced off-target toxicity compared to conventional chemotherapy.
- Experimental Validation: Further experimental validation is warranted to confirm the clinical utility of these markers. This would involve:
- Protein expression analysis (e.g., immunohistochemistry, flow cytometry) on a larger cohort of colon cancer samples.
- Functional studies (e.g., gene knockdown/overexpression in cell lines, organoids, or in vivo models) to elucidate their precise roles in tumor growth, invasion, and metastasis.
- Clinical correlation studies to assess their association with clinical parameters like tumor stage, response to therapy, and patient survival.
17. Macrophage Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies condition-specific surfaceome markers for Macrophage cells by comparing their expression in tumor tissue versus adjacent normal tissue from single-cell RNA-seq data of human Colon samples. The plot_markers_and_expression_dot tool was used to visualize the expression (mean expression by color intensity) and prevalence (fraction of cells expressing the gene by dot size) of up to 50 surfaceome markers per condition. This helps to characterize the distinct phenotypic states of macrophages in different tissue microenvironments.
Visual Summary
The dot plot visualizes the expression of 30 surfaceome markers across various Macrophage samples, grouped by condition: 'tumor' (top section) and 'adjacent_normal' (bottom section).
- Differential Expression Profile: A striking pattern emerges where a large number of surfaceome markers exhibit significantly higher expression levels (darker red dots) and broader prevalence (larger dot sizes) in Macrophages from tumor samples compared to those from adjacent normal tissue. This indicates a distinct activation or polarization state of tumor-associated macrophages (TAMs).
- Tumor-Associated Macrophage (TAM) Signature: Genes such as CD44, PLAUR, SLC2A3, ITGB1, C3AR1, FCGR3A, C5AR1, SLC11A1, SIRPA, CD83, PLXDC2, FPR1, GPNMB, SERINC1, SCARB2, SPPL2A, HM13, LAIR1, TLR2, ICAM1, SLC3A2, HAVCR2, HBEGF, TM9SF3, and ITGAX show strong upregulation in tumor Macrophages. These markers are consistently expressed across most tumor samples and often at high mean expression levels.
- Adjacent Normal Macrophages: In contrast, Macrophages from adjacent normal tissue generally display lower expression and prevalence of most of these markers. There are few, if any, markers that show a distinctly high and specific expression pattern solely in adjacent normal Macrophages relative to tumor Macrophages in this selected set. This suggests that the tumor microenvironment drives a significant transcriptional shift in Macrophage surface protein expression.
Biological Interpretation
The observed differential surfaceome marker expression points to significant functional adaptations of Macrophages in the tumor microenvironment (TAMs) of colorectal cancer compared to their counterparts in healthy adjacent tissue. Many of the highly expressed markers in TAMs are associated with pro-tumor functions:
- Adhesion, Migration, and Invasion: Markers like CD44 (involved in cell-cell and cell-matrix interactions, migration, and stemness [1]), PLAUR (Urokinase Plasminogen Activator Receptor, crucial for cell adhesion, migration, and proteolysis, often associated with cancer invasion [2]), ITGB1 (Integrin Beta 1, mediating cell-matrix interactions and signaling [3]), and ICAM1 (Intercellular Adhesion Molecule 1, involved in immune cell trafficking and inflammation [4]) are highly expressed. This suggests that TAMs in colon tumors are actively engaged in migration, tissue remodeling, and interaction with other cells within the tumor microenvironment, potentially facilitating tumor growth and metastasis.
Immune Modulation and Suppression:
- SIRPA (Signal Regulatory Protein Alpha, also known as CD172a) is a key immune checkpoint molecule on myeloid cells that interacts with CD47 on cancer cells, delivering a "don't eat me" signal to inhibit phagocytosis [5]. Its high expression indicates a potential mechanism for TAMs to evade clearance by other immune cells or for tumor cells to evade macrophage-mediated phagocytosis.
- TLR2 (Toll-like Receptor 2) is a pattern recognition receptor involved in innate immunity. While TLR2 activation can be pro-inflammatory, in the tumor context, it can also drive immunosuppressive functions in TAMs, contributing to immune evasion [6].
- CD83 is expressed on various immune cells and can modulate immune responses, including T cell activation and differentiation [7].
- LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1) is an inhibitory receptor that can suppress immune cell activation [8].
- Metabolic Reprogramming: SLC2A3 (GLUT3), a glucose transporter, suggests altered glucose metabolism in TAMs, potentially indicative of aerobic glycolysis (the Warburg effect), which is common in cancer cells and can be adopted by TAMs to support their high metabolic demands in the TME [9]. SLC11A1 and SLC3A2 are other solute carrier proteins, further hinting at metabolic adaptations.
- Complement and Fc Receptor Pathways: Upregulation of C3AR1 and C5AR1 (complement receptors [10]) and FCGR3A (Fc gamma receptor IIIA/CD16A [11]) suggests altered engagement with complement components and immune complexes, which can influence TAM-mediated phagocytosis, inflammation, and antibody-dependent cellular cytotoxicity (ADCC) in the tumor.
- Growth Factor Signaling: HBEGF (Heparin-Binding EGF-like Growth Factor) is a potent mitogen and chemotactic factor, implicated in cell proliferation, migration, and angiogenesis. Secreted by macrophages, it can directly promote tumor growth and metastasis [12].
- Myeloid Cell Lineage Markers: ITGAX (Integrin Alpha X, also known as CD11c) is a marker typically associated with dendritic cells but also found on certain macrophage subsets, indicating their differentiation state or functional role [13].
The collective upregulation of these surfaceome markers strongly suggests that Macrophages in colon tumors adopt a distinct, pro-tumoral phenotype that facilitates tumor progression, immune evasion, and metastasis.
Clinical or Translational Implications
The identified condition-specific surfaceome markers for Macrophages in colon cancer hold significant clinical and translational potential.
- Biomarkers for Diagnosis and Prognosis: The unique surfaceome signature of TAMs (e.g., high expression of CD44, PLAUR, SIRPA, GPNMB, HBEGF, TLR2, ITGB1, CD83, ITGAX) could serve as a valuable set of diagnostic or prognostic biomarkers for colorectal cancer. These markers could be detected via immunohistochemistry (IHC) on tumor biopsies, flow cytometry on dissociated tumor cells, or even potentially in liquid biopsies (e.g., exosomal markers) to identify TAM infiltration, assess disease progression, or predict treatment response.
Therapeutic Targets for Immunomodulation:
- Targeting the SIRPA-CD47 Axis: The prominent expression of SIRPA on tumor Macrophages makes this pathway a compelling therapeutic target. Blocking the SIRPA-CD47 interaction (e.g., with anti-SIRPA or anti-CD47 antibodies) aims to unleash macrophage phagocytosis of cancer cells, a strategy currently under active investigation in various cancers [14].
- Inhibiting Adhesion/Migration: Modulating or blocking surface molecules like CD44, PLAUR, ITGB1, or ICAM1 could inhibit the recruitment of pro-tumoral macrophages into the tumor, reduce their interaction with cancer cells, and potentially impede metastasis.
- Reprogramming TAMs: Markers like TLR2 could be explored for their potential to "re-educate" TAMs from an immunosuppressive, pro-tumoral phenotype towards an anti-tumoral, M1-like state using specific agonists or antagonists, thereby enhancing anti-cancer immunity.
- Blocking Growth Factor Signaling: Inhibiting HBEGF signaling, potentially by targeting its receptor (EGFR, not shown here but known to interact with HBEGF), could reduce tumor growth, angiogenesis, and proliferation driven by TAMs.
- Experimental Validation: These identified surface markers are excellent candidates for further experimental validation. This would involve:
- Validation in patient cohorts: Confirming expression patterns using IHC or multiplex immunofluorescence on a larger cohort of human colon cancer tissues.
- Functional assays: Investigating the impact of modulating these surface markers (e.g., using genetic knockdown/knockout or antibody blockade) on macrophage polarization, phagocytosis, T-cell activation, and tumor growth *in vitro* and *in vivo* (e.g., in organoid models or xenograft mouse models).
The distinct surfaceome profile of Macrophages in colon cancer highlights their active role in disease pathogenesis and offers a rich landscape of potential targets for novel immunotherapeutic strategies.
---
References:
- CD44: GeneCards entry for CD44. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44
- PLAUR: GeneCards entry for PLAUR. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PLAUR
- ITGB1: GeneCards entry for ITGB1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ITGB1
- ICAM1: GeneCards entry for ICAM1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ICAM1
- SIRPA-CD47 Axis: PubMed search for "SIRPA CD47 cancer immunotherapy". https://pubmed.ncbi.nlm.nih.gov/?term=SIRPA+CD47+cancer+immunotherapy
- TLR2 in TAMs: PubMed search for "TLR2 tumor associated macrophages". https://pubmed.ncbi.nlm.nih.gov/?term=TLR2+tumor+associated+macrophages
- CD83: GeneCards entry for CD83. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD83
- LAIR1: GeneCards entry for LAIR1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=LAIR1
- SLC2A3/GLUT3 in TAMs: PubMed search for "GLUT3 tumor associated macrophages metabolism". https://pubmed.ncbi.nlm.nih.gov/?term=GLUT3+tumor+associated+macrophages+metabolism
- C3AR1 and C5AR1: GeneCards entry for C3AR1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=C3AR1 and C5AR1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=C5AR1
- FCGR3A: GeneCards entry for FCGR3A. https://www.genecards.org/cgi-bin/carddisp.pl?gene=FCGR3A
- HBEGF: GeneCards entry for HBEGF. https://www.genecards.org/cgi-bin/carddisp.pl?gene=HBEGF
- ITGAX (CD11c): GeneCards entry for ITGAX. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ITGAX
- SIRPA-CD47 immunotherapy: PubMed search for "SIRPA CD47 immunotherapy cancer". https://pubmed.ncbi.nlm.nih.gov/?term=SIRPA+CD47+immunotherapy+cancer
18. Condition-Specific Surfaceome Markers in Colon Fibroblasts
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify and visualize condition-specific surfaceome markers in Fibroblast cells from human colon tissue, comparing "adjacent normal" and "tumor" conditions. The provided dot plot displays the expression patterns of these markers across various fibroblast clusters (represented on the y-axis), with genes grouped by their preferential expression in either the "adjacent normal" or "tumor" context (x-axis). The size of each dot signifies the fraction of cells within a cluster expressing a particular gene, while the color intensity reflects the mean expression level of that gene. This approach allows for the discovery of cell surface proteins that are distinctly regulated in fibroblasts contributing to the tumor microenvironment compared to those in healthy adjacent tissue.
Visual Summary
The dot plot effectively illustrates clear distinctions in surfaceome marker profiles between fibroblasts in adjacent normal tissue and those within the tumor microenvironment.
- Adjacent Normal-Specific Markers: A set of approximately 21 genes is predominantly expressed in fibroblast clusters originating from "adjacent normal" colon tissue. These include markers such as *PLPP3*, *SCARA5*, *GPNMB*, *ABCA8*, *PI16*, *TGFBR3*, *CADM3*, *CLDN11*, and *CD34*. These genes show strong mean expression and high prevalence (large, dark red dots) in the left block of the plot, corresponding to adjacent normal samples, but are largely absent or expressed at very low levels in tumor fibroblasts.
- Tumor-Specific Markers: A much larger panel of approximately 39 genes demonstrates high expression and prevalence specifically in fibroblasts from "tumor" tissue. Key examples include *PDGFRB*, *CDH11*, *ANTXR1*, *CD44*, *ITGAV*, *TM9SF3*, *TGOLN2*, *PTTG1IP*, *TMEM123*, *ITGA1*, *PMEPA1*, *HM13*, *SGCB*, *SSR1*, *TMEM30A*, *CD46*, *NECTIN2*, *ITGA5*, *GLIPR1*, *BMPR2*, *NPTN*, *PDLIM5*, *MYOF*, *SLC3A2*, *SLC2A3*, *TMED7*, *F2R*, *FAT1*, and *SLC39A6*. These markers are concentrated in the right block of the plot, exhibiting dark red, large dots in tumor-associated fibroblast clusters, while showing minimal or no expression in adjacent normal counterparts.
- Fibroblast Heterogeneity: The plot also suggests functional heterogeneity within the fibroblast population. Multiple fibroblast clusters (rows) are evident, each displaying distinct combinations and intensities of marker expression. This is particularly pronounced in the tumor microenvironment, where different fibroblast sub-clusters show varying levels of activation markers, hinting at diverse roles of cancer-associated fibroblasts (CAFs). The presence of specific subgroups within the tumor area, highlighted by the red boxes, further supports this heterogeneity.
Biological Interpretation
The differential expression of these surfaceome markers provides significant biological insights into the activation and functional specialization of fibroblasts in colorectal cancer. The transition of quiescent fibroblasts to activated cancer-associated fibroblasts (CAFs) is a critical event in tumor progression, marked by profound changes in their gene expression profile.
- Markers of Normal Stroma: Genes like *GPNMB* (Glycoprotein Non-metastatic Melanoma Protein B) are often associated with the remodeling of the extracellular matrix and play roles in cell adhesion and growth [NCBI]. *CLDN11* (Claudin-11) is a tight junction protein, important for maintaining epithelial and endothelial barrier integrity [GeneCards]. *CD34*, while primarily known for hematopoietic stem cells, also marks specific subsets of stromal progenitor cells and endothelial cells, suggesting its role in normal tissue homeostasis and specific stromal niches in the healthy colon [GeneCards]. The downregulation or absence of these markers in tumor fibroblasts suggests a shift away from normal stromal maintenance functions.
- Hallmarks of Cancer-Associated Fibroblasts (CAFs): The robust upregulation of numerous surface markers in tumor fibroblasts strongly indicates their activation into CAFs, which are key drivers of tumor growth, invasion, and metastasis.
- Growth Factor Signaling and ECM Remodeling: *PDGFRB* (Platelet-Derived Growth Factor Receptor Beta) is a canonical marker for activated fibroblasts and pericytes, crucial for mediating interactions within the tumor stroma, promoting angiogenesis, and driving fibrotic responses [PubMed Search]. Integrins such as *ITGAV* (Integrin Alpha V), *ITGA1* (Integrin Alpha 1), and *ITGA5* (Integrin Alpha 5) are vital for cell-extracellular matrix (ECM) interactions, which are highly dynamic in the tumor microenvironment. Their upregulation facilitates CAF-mediated matrix remodeling, tumor invasion, and metastasis [NCBI].
- Cell Adhesion and Migration: *CDH11* (Cadherin-11) is involved in cell-cell adhesion and has been implicated in CAF-driven tumor progression, including invasion and epithelial-mesenchymal transition [GeneCards]. *CD44* is a widely recognized adhesion molecule and a cancer stem cell marker, playing roles in cell migration, invasion, and immune evasion [NCBI].
- TGF-β Pathway Activation: *PMEPA1* (Prostate Transmembrane Protein, Androgen Induced 1) is a TGF-β inducible gene that can modulate TGF-β signaling, a critical pathway for CAF activation and pro-tumorigenic functions, including immune suppression and fibrogenesis [NCBI]. Its high expression suggests active TGF-β signaling in tumor fibroblasts.
- Metabolic Reprogramming: The presence of solute carrier family members like *SLC3A2* (CD98) and *SLC2A3* (GLUT3) suggests altered metabolic demands within CAFs, which support their high proliferative activity and provide nutrients to tumor cells in the hypoxic and nutrient-deprived tumor microenvironment [GeneCards].
- Other Relevant Markers: *ANTXR1* (Anthrax Toxin Receptor 1, also known as TEM8) is expressed on tumor endothelial cells and CAFs, contributing to angiogenesis and tumor growth [NCBI]. *F2R* (Coagulation Factor II Receptor, PAR1), a thrombin receptor, mediates various cellular responses, including proliferation and migration, which are relevant in the inflammatory and procoagulant tumor microenvironment.
Clinical or Translational Implications
The identification of these condition-specific surfaceome markers in colon fibroblasts has significant clinical and translational potential, particularly for developing new therapeutic strategies and improving diagnostic/prognostic tools.
- Therapeutic Targets: Surface markers are ideal candidates for targeted therapies due to their accessibility on the cell membrane.
- Direct Targeting of CAFs: Genes such as *PDGFRB*, *ITGAV/ITGA1/ITGA5*, *CDH11*, *CD44*, and *ANTXR1*, highly expressed on tumor-associated fibroblasts, represent promising targets. Inhibiting their function with small molecules or antibodies, or leveraging them for antibody-drug conjugates (ADCs) or CAR-T cell therapies, could selectively modulate the tumor microenvironment and hinder tumor progression. For instance, anti-PDGFRβ therapies have shown promise in preclinical and clinical studies to target pericytes and CAFs in various cancers [PubMed Search].
- Disrupting CAF Functions: Targeting integrins (ITGAV, ITGA1, ITGA5) could disrupt critical CAF-ECM interactions, thereby reducing tumor stiffness, inhibiting invasion, and preventing metastasis [NCBI].
- Modulating Pro-tumorigenic Pathways: The upregulation of *PMEPA1* in CAFs indicates active TGF-β signaling. Targeting this pathway, possibly by modulating PMEPA1's effectors, could mitigate the pro-tumorigenic and immunosuppressive effects of CAFs.
- Diagnostic and Prognostic Biomarkers: The distinct expression profiles of these surface markers could be utilized for diagnostic purposes, aiding in the differentiation of tumor tissue from normal adjacent tissue based on fibroblast signatures. Furthermore, specific patterns of CAF marker expression might correlate with disease stage, aggressiveness, or response to existing therapies, thereby offering valuable prognostic information. For example, the presence of certain CAF subpopulations defined by unique surface markers has been linked to patient outcomes in colorectal cancer.
- Experimental Validation and Imaging: These identified markers provide a strong foundation for further experimental validation using techniques such as immunohistochemistry, immunofluorescence, flow cytometry, or spatial transcriptomics on patient tissue samples. This validation is crucial to confirm their specific localization, functional roles, and clinical relevance. Moreover, these markers could be explored as targets for developing novel imaging agents to non-invasively detect and monitor CAF populations in vivo, providing insights into tumor progression and response to therapy.
This comprehensive profiling of fibroblast surfaceome in the context of colon cancer significantly enhances our understanding of CAF biology and opens new avenues for targeted therapeutic interventions.
19. CD4 T Cell Surfaceome Markers in Colon Cancer Conditions
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify condition-specific surfaceome markers in CD4+ T cells by comparing different conditions (likely tumor vs. adjacent normal, given the context and 'tumor' label in the plot). The plot_markers_and_expression_dot tool was used to visualize the mean expression and fraction of cells expressing these markers across various CD4+ T cell clusters/samples. The parameters ensured that only surfaceome markers with significant differential expression (fold change > 1.5, p-value < 0.05, and expression score cutoffs) were included, with up to 50 markers per condition.
Visual Summary
The dot plot displays the expression profiles of identified surfaceome markers for CD4+ T cells. Each row (C###) represents a distinct cluster or sample group of CD4+ T cells, and each column represents a specific gene. The size of the dot corresponds to the fraction of cells within that group expressing the gene, while the intensity of the red color indicates the mean expression level of the gene in that group.
A clear pattern emerges where a significant portion of the CD4+ T cell clusters, particularly those labeled or associated with the "tumor" condition (highlighted by the red boxes), show strong and widespread expression of a distinct set of surface markers. In contrast, other clusters (likely representing adjacent normal tissue or less activated states) exhibit lower expression levels and/or lower prevalence of these markers.
Key observations within the highlighted tumor-associated clusters include strong co-expression of:
- Immune checkpoint molecules: CTLA4, TIGIT.
- Co-stimulatory receptors: TNFRSF4 (OX40), TNFRSF18 (GITR), ICOS.
- MHC Class II molecules and associated chain: HLA-DRA, HLA-DRB1, HLA-DPB1, CD74.
- Other functional molecules: ENTPD1, BSG (CD147), BST2 (CD317), IL2RB, IL2RG.
The clusters in the middle section of the plot (within the red boxes) display the most intense and widespread red dots for the identified markers, indicating high mean expression and a large fraction of cells expressing these genes within these tumor-associated CD4+ T cell populations.
Biological Interpretation
The distinct surfaceome signature observed in tumor-associated CD4+ T cells suggests a specific functional state of these cells within the colorectal tumor microenvironment.
- T Cell Activation and Exhaustion/Regulation: The simultaneous upregulation of co-stimulatory molecules (TNFRSF4/OX40 [GeneCards: OX40], TNFRSF18/GITR [GeneCards: GITR], ICOS [GeneCards: ICOS]) and immune checkpoint inhibitors (CTLA4 [GeneCards: CTLA4], TIGIT [GeneCards: TIGIT]) points towards a population of CD4+ T cells that are actively engaged in the immune response but are also undergoing regulation or exhaustion. OX40 and GITR are known to promote T cell activation and survival, while CTLA4 and TIGIT deliver inhibitory signals, often leading to T cell anergy or exhaustion in chronic stimulation contexts like cancer.
- Antigen Presentation and Immune Signaling: The high expression of MHC Class II molecules (HLA-DRA, HLA-DRB1, HLA-DPB1) and the invariant chain CD74 on CD4+ T cells in the tumor microenvironment is notable. While primarily expressed by antigen-presenting cells, activated CD4+ T cells can also upregulate MHC Class II, suggesting a potent activation state and potentially a role in unconventional antigen presentation or immune regulation within the tumor. This could also imply a strong interaction with other immune cells.
- Immunosuppressive Microenvironment: The presence of ENTPD1 (CD39) [GeneCards: ENTPD1] further supports the concept of an immunosuppressive microenvironment. CD39 is an ectonucleotidase that, along with CD73, degrades ATP into adenosine, which is a potent immunosuppressive molecule in the tumor context, contributing to T cell dysfunction.
- Other Markers: BSG (CD147) is involved in various processes including cell growth, invasion, and inflammation, and its expression on T cells can influence their function and interaction with tumor cells. BST2 (CD317) is an interferon-inducible protein, suggesting an ongoing inflammatory response. IL2RB (CD122) and IL2RG (CD132) are components of cytokine receptors, indicating responsiveness to various cytokines, including IL-2, which is critical for T cell proliferation and survival, but can also be involved in Treg function.
These findings collectively suggest that CD4+ T cells in colon tumors are highly activated but concurrently experience significant regulatory pressures or exhaustion, contributing to an overall immunosuppressive environment. These markers differentiate tumor-associated CD4+ T cells from their counterparts in adjacent normal tissue.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in CD4+ T cells from colon tumors have significant clinical and translational implications:
- Biomarkers for Disease State and Prognosis: The unique signature of activated and exhausted CD4+ T cells could serve as prognostic biomarkers in colon cancer, identifying patients with specific immune microenvironments that might correlate with disease progression or response to therapy.
- Therapeutic Targets for Immunomodulation: Several identified markers are well-established or emerging targets for cancer immunotherapy:
- Immune Checkpoint Blockade: High expression of CTLA4 and TIGIT suggests that these CD4+ T cells could be targets for existing (e.g., anti-CTLA4 antibodies) or experimental checkpoint inhibitors to reverse T cell exhaustion and enhance anti-tumor immunity. [PubMed search: CTLA4 TIGIT immunotherapy colorectal cancer]
- Co-stimulatory Agonists: The presence of OX40 and GITR indicates potential for T cell activation therapies using agonistic antibodies against these receptors to boost anti-tumor immune responses. [PubMed search: OX40 agonist GITR agonist cancer therapy]
- Adenosinergic Pathway Inhibition: Upregulation of ENTPD1 (CD39) highlights the adenosinergic pathway as a potential immunosuppressive mechanism. Inhibitors of CD39 or CD73 could be explored to counteract adenosine-mediated immune suppression and improve T cell function. [PubMed search: CD39 inhibitors cancer immunotherapy]
- Experimental Validation and Patient Stratification: The specific CD4+ T cell subsets characterized by these markers warrant further experimental validation through functional assays (e.g., cytokine production, proliferation) to confirm their precise roles in tumor immunity. This detailed characterization could enable better stratification of patients for targeted immunotherapies based on their specific T cell immune profiles within the tumor microenvironment.
20. Intestinal Epithelial Cells in Colon Cancer Exhibit Widespread Upregulation of Cell Cycle Genes
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the differential expression of a curated set of cell cycle pathway-related genes within Intestinal Epithelial cells, comparing tumor tissue to adjacent normal tissue. The aim is to identify specific cell cycle regulators that are significantly dysregulated in tumor-origin cells, providing insights into the proliferative state characteristic of colorectal cancer. The plot_box_for_gene_expression_with_signif_difference tool was used to visualize gene expression distributions and highlight statistically significant differences.
Visual Summary
The boxplots illustrate the expression levels (represented as sample means) of 60 cell cycle-related genes in Intestinal Epithelial cells across tumor and adjacent normal conditions. A striking and consistent pattern emerges: the vast majority of these genes show significantly higher expression in tumor tissue compared to adjacent normal tissue.
Key visual observations include:
- Predominant Upregulation in Tumor: Nearly all displayed cell cycle genes exhibit elevated expression in the "tumor" group (blue boxes) compared to the "adjacent_normal" group (orange boxes). This suggests a widespread activation of the cell cycle machinery in cancerous epithelial cells.
- Statistical Significance: A large number of genes demonstrate statistically significant differences, with p-values often less than 0.01 or 0.05, and sometimes less than 0.001. This reinforces the robustness of the observed upregulation.
- Diverse Cell Cycle Functions: The upregulated genes span various aspects of the cell cycle, including DNA replication (e.g., MCM and ORC complexes), cell cycle progression (e.g., Cyclins, CDKs, CDC proteins), mitotic checkpoints (e.g., BUB3, MAD2L1), and DNA damage response (e.g., ATM, CHEK1, GADD45A).
- Consistent Trend: The boxplots show clear shifts in the median expression and overall distribution, with the tumor condition typically having higher median values and often a broader range of expression, indicating increased proliferative activity across different samples.
Biological Interpretation
The observed widespread upregulation of cell cycle genes in Intestinal Epithelial cells of colon tumor tissue provides strong biological evidence for uncontrolled proliferation, a hallmark of cancer. This finding is consistent with the nature of Intestinal Epithelial cells being the cell of origin for colorectal adenocarcinoma.
Specifically, the significant upregulation of the following categories of genes highlights distinct aspects of tumor biology:
- DNA Replication Initiation and Elongation: Genes like MCM7, MCM3, MCM4, MCM5, MCM6 (Minichromosome Maintenance Complex components) and ORC2, ORC3, ORC4, ORC6 (Origin Recognition Complex components) are crucial for initiating and unwinding DNA for replication. Their increased expression indicates a highly active S-phase in tumor cells, supporting rapid DNA synthesis to fuel cell division PubMed Search: MCM ORC cancer proliferation.
Cell Cycle Progression Regulators
- Cyclins and Cyclin-Dependent Kinases (CDKs): CCNB1, CCNB2 (Cyclin B), CCND1, CCND3 (Cyclin D), CDK4, CDK6, CDK7, CDK1 are key drivers of cell cycle transitions. Their overexpression drives cells through G1/S and G2/M checkpoints, leading to accelerated proliferation GeneCards: CCND1.
- CDC (Cell Division Cycle) Proteins: CDC20, CDC23, CDC26, CDC27 are involved in various stages of cell division, often as activators or components of the Anaphase-Promoting Complex/Cyclosome (APC/C). Their upregulation suggests an activated and potentially dysregulated mitotic process.
- Mitotic Checkpoint and Spindle Assembly: Genes such as BUB3 and MAD2L1 (components of the spindle assembly checkpoint) and ANAPC1, ANAPC5, ANAPC7, ANAPC10 (components of the APC/C) are crucial for ensuring proper chromosome segregation during mitosis. Their elevated expression might reflect increased mitotic activity or a compensatory response to genomic instability often seen in cancer. PTTG1 (Securin), which inhibits sister chromatid separation until anaphase, is also significantly upregulated, further indicating active and potentially faulty mitosis.
- DNA Damage Response and Checkpoint Activation: Upregulation of ATM (Ataxia Telangiectasia Mutated), CHEK1 (Checkpoint Kinase 1), PRKDC (DNA-PK catalytic subunit), WEE1, and GADD45A/B might suggest increased genomic stress or an active DNA damage response within tumor cells due to rapid, often error-prone replication. These pathways attempt to repair damage or halt the cell cycle, but in cancer, they are often overridden or ineffective, contributing to genomic instability.
- Transcription Factors and Co-regulators: Genes like E2F3, E2F4, TFDP1, TFDP2 (E2F family transcription factors) are critical for driving the expression of genes required for DNA synthesis and cell cycle progression. Their upregulation further confirms an aggressive proliferative program. MYC, a potent oncogene, also shows a trend towards upregulation (p=0.06), consistent with its role in promoting cell growth and division.
Tumor Suppressors/Antagonists with Complex Roles
- CDKN1B (p27): While typically a Cdk inhibitor that arrests cell cycle, its upregulation here is noteworthy. In some cancers, p27 can be mislocalized or degraded, rendering it ineffective despite high expression, or it can even have pro-tumorigenic roles PubMed Search: CDKN1B cancer complex role. Its presence could indicate a compensatory mechanism that is ultimately overwhelmed by other proliferative signals.
- RB1 (Retinoblastoma protein): A canonical tumor suppressor, its upregulation (p < 0.001) in tumor cells alongside E2F activation is unexpected if RB1 is functionally active. This could suggest that despite increased mRNA, the protein might be functionally inactivated (e.g., by hyperphosphorylation) or that tumor cells have developed mechanisms to bypass RB1-mediated cell cycle control.
Collectively, these findings paint a picture of Intestinal Epithelial cells in colon tumors aggressively driving cell division through multiple mechanisms, consistent with their malignant transformation.
Clinical or Translational Implications
The pervasive upregulation of cell cycle genes in Intestinal Epithelial cells in tumor tissue has several clinical and translational implications:
- Biomarkers of Proliferation and Prognosis: The expression levels of these cell cycle genes (e.g., MCMs, Cyclins, CDKs) could serve as robust biomarkers for assessing tumor proliferation rates, predicting disease aggressiveness, and potentially guiding prognosis in colorectal cancer patients UniProt: MCM7.
- Therapeutic Targets: Many of the upregulated genes represent established or emerging targets for cancer therapy:
- CDK Inhibitors: The upregulation of CDKs (CDK4, CDK6, CDK1) and Cyclins (CCND1, CCNB1/2) reinforces the rationale for CDK inhibitors, which are already used in other cancers (e.g., breast cancer) and are under investigation for colorectal cancer.
- DNA Damage Response Inhibitors: Elevated ATM, CHEK1, and PRKDC suggest that tumors might be particularly reliant on DNA damage response pathways to cope with replication stress. Inhibitors of these pathways could be effective, especially in combination with chemotherapy or radiation.
- APC/C Inhibitors: Components of the APC/C are highly expressed, indicating their potential as targets for novel mitotic inhibitors.
- Understanding Treatment Resistance: The complex interplay, such as the simultaneous upregulation of the tumor suppressor RB1 alongside its downstream targets E2F, highlights the intricate biology of cancer cells. This suggests that simply targeting individual components might be insufficient if compensatory mechanisms or functional inactivation events (e.g., post-translational modifications) are at play. Further investigation into the functional status of these proteins, beyond mRNA expression, is warranted for effective therapeutic development.
21. Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Ontology (GO) enrichment results (GSA) for Intestinal Epithelial cells. The results are displayed as bar plots, showing significantly enriched GO terms ranked by statistical significance (-log(p-val) and -log(q-val)). Two comparisons are evaluated:
- Diploid_vs_others: Genes upregulated in diploid Intestinal Epithelial cells compared to all other cells (likely including aneuploid cells, which are often associated with malignancy).
- tumor_vs_others: Genes upregulated in Intestinal Epithelial cells specifically from tumor tissue compared to cells from other conditions (e.g., adjacent normal tissue).
This allows us to understand the distinct biological processes characterizing non-malignant vs. malignant epithelial cells, and those specific to the tumor microenvironment in colon tissue.
Visual Summary
The bar plots display the top 60 enriched GO terms for each comparison. The length of the bars corresponds to the negative logarithm of the p-value and adjusted p-value (q-value), indicating the statistical significance of the enrichment.
For the Diploid_vs_others comparison:
- The most significantly enriched terms are highly dominated by immune response pathways, including viral immunity, allograft rejection, antigen processing and presentation, and particularly the "Intestinal immune network for IgA production."
- A term related to normal epithelial function, "Mineral absorption," is also present.
For the tumor_vs_others comparison:
- This plot shows a much wider range of highly significant terms.
- Key enriched categories include protein homeostasis (e.g., Ubiquitin mediated proteolysis, Protein processing in endoplasmic reticulum, Ribosome, RNA transport), cell cycle regulation ("Cell cycle," "Cellular senescence"), and various infection-related pathways (e.g., Salmonella infection, Viral carcinogenesis, Pathogenic Escherichia coli infection).
- Signaling pathways like "mTOR signaling pathway" and "Insulin signaling pathway" are also prominent.
- Interestingly, several neurodegenerative disease pathways (e.g., Amyotrophic lateral sclerosis, Huntington disease, Alzheimer disease) appear.
Biological Interpretation
Intestinal Epithelial Cells: Diploid_vs_others
The strong enrichment of immune-related GO terms in diploid Intestinal Epithelial cells suggests that these non-malignant cells are actively involved in the host's immune defense and surveillance mechanisms.
- Immune Surveillance and Response: Terms like "Viral myocarditis," "Allograft rejection," "Antigen processing and presentation," and "Epstein-Barr virus infection" indicate a robust capacity for detecting and responding to foreign antigens and pathogens.
- Mucosal Immunity: The prominent "Intestinal immune network for IgA production" highlights the crucial role of diploid intestinal epithelial cells in maintaining gut barrier integrity and facilitating adaptive immune responses in the mucosa, which is vital for defending against luminal pathogens and maintaining gut homeostasis [PubMed Search]. This suggests a healthy, functional epithelial state.
- Normal Epithelial Function: "Mineral absorption" further underscores the metabolic and functional role of these cells in the healthy colon.
Intestinal Epithelial Cells: tumor_vs_others
The GO enrichment in tumor-associated Intestinal Epithelial cells reveals a profound shift in cellular biology, reflecting malignant transformation and adaptation to the tumor microenvironment.
- Altered Protein Homeostasis and Metabolism: Highly significant terms such as "Ubiquitin mediated proteolysis," "Protein processing in endoplasmic reticulum," "Endocytosis," "Spliceosome," "RNA transport," "Ribosome," and "Autophagy" point to a drastically rewired cellular machinery focused on protein synthesis, modification, and degradation. This reflects the high metabolic demand and rapid proliferation characteristic of cancer cells [PubMed Search].
- Cell Cycle Deregulation: The direct enrichment of "Cell cycle" is a hallmark of cancer, indicating uncontrolled proliferation. "Cellular senescence" also appears, which can represent a tumor-suppressive mechanism or contribute to tumor progression via the senescence-associated secretory phenotype (SASP).
- Dysregulated Signaling Pathways: "mTOR signaling pathway" and "Insulin signaling pathway" are critical regulators of cell growth, proliferation, and metabolism, and their activation is frequently observed in various cancers, including colorectal cancer, driving tumor progression [PubMed Search].
- Host-Pathogen Interactions and Carcinogenesis: The enrichment of multiple infection-related pathways (e.g., "Salmonella infection," "Viral carcinogenesis," "Pathogenic Escherichia coli infection") suggests that tumor cells may either exploit these pathways, alter their response to pathogens, or that pathogen-driven inflammation and infection contribute to tumorigenesis in the colon [PubMed Search]. "Viral carcinogenesis" directly implies a role for viral agents.
- Shared Stress Responses: The presence of neurodegenerative disease pathways (e.g., "Amyotrophic lateral sclerosis," "Huntington disease") is intriguing. While not directly indicating neurological disease in the colon, these pathways often involve common cellular mechanisms of protein misfolding, aggregation, and stress responses, suggesting that tumor cells might engage similar stress adaptation or dysregulation processes.
Clinical or Translational Implications
The distinct biological signatures of diploid versus tumor Intestinal Epithelial cells provide valuable insights into colon cancer development and potential therapeutic strategies.
- Therapeutic Targets: The significant dysregulation of protein homeostasis (ubiquitin-proteasome system, ER processing), cell cycle, and growth-promoting pathways (mTOR, insulin signaling) in tumor cells highlights these as promising targets for anti-cancer therapies in colorectal cancer. Inhibiting these pathways could disrupt tumor growth and survival.
- Role of Infection in Carcinogenesis: The strong enrichment of "Viral carcinogenesis" and bacterial infection pathways suggests that investigating the precise role of specific pathogens in driving or modulating colon cancer progression could lead to novel preventive or therapeutic interventions, possibly including vaccines or antimicrobial therapies in select patient populations.
- Biomarker Discovery: The differentially enriched GO terms could serve as a foundation for identifying novel biomarkers that distinguish healthy from malignant epithelial cells, aiding in early detection, prognosis, or monitoring treatment response.
- Understanding Tumor Microenvironment: The contrast between the immune-active diploid cells and the reprogrammed tumor cells underscores the complex immune evasion mechanisms and altered host-pathogen interactions within the tumor microenvironment, which are critical for developing effective immunotherapies.
22. Gene Set Enrichment Analysis across Major Cell Types in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Set Enrichment Analysis (GSEA) results across major cell types identified in single-cell RNA sequencing data from human colon tissue. The dot plot visualizes the enrichment of 80 significant gene sets (pathways) for each cell type, comparing cells from either tumor or adjacent normal tissue contexts against all other cells of the same type (or Diploid vs. others for Intestinal Epithelial cells).
Each dot represents a specific pathway within a cell type/condition comparison. The size of the dot corresponds to the statistical significance (-log10(P-value)), with larger dots indicating higher significance. The color of the dot reflects the Normalized Enrichment Score (NES), where red indicates positive enrichment (pathway upregulated in the test condition/cell type) and blue indicates negative enrichment (pathway downregulated). This allows us to identify cell type-specific biological processes that are distinctly active or suppressed in the tumor microenvironment compared to the adjacent normal tissue.
Visual Summary
The dot plot effectively summarizes the pathway enrichment landscape across various major cell types and conditions.
- Distinct Cell Type-Specific Signatures: Different cell types exhibit unique pathway enrichment patterns, reflecting their specialized functions. For instance, Intestinal Epithelial cells in tumor show strong enrichment for cell proliferation pathways, while T cells and Macrophages in tumor show enrichment for immune activation pathways.
- Tumor vs. Adjacent Normal Differences: For most cell types, there are clear differences in pathway enrichment when comparing the "tumor_vs_others" condition to "adjacent_normal_vs_others." Pathways associated with cancer hallmarks (e.g., cell cycle, immune response, angiogenesis, ECM remodeling) are generally upregulated in tumor-associated cells and downregulated or less enriched in adjacent normal cells.
- Proliferation and Cancer Pathways in Epithelial Cells: The Intestinal Epithelial cells from tumor samples show prominent positive enrichment for Cell cycle, DNA replication, Pathways in cancer, Ribosome biogenesis in eukaryotes, and Proteasome, indicating high proliferative activity and cancer-associated molecular programs.
- Immune Activation in T cells and Macrophages: T cell CD4+, T cell CD8+, and Macrophages in the tumor environment display significant positive enrichment for immune-related pathways such as Antigen processing and presentation, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, NF-kappa B signaling pathway, and Th1 and Th2 cell differentiation, suggesting active immune responses within the tumor.
- Stromal Remodeling and Angiogenesis: Fibroblasts and Endothelial cells in the tumor show strong enrichment for pathways like Focal adhesion, ECM-receptor interaction, VEGF signaling pathway, PI3K-Akt signaling pathway, and MAPK signaling pathway, consistent with their roles in extracellular matrix remodeling and angiogenesis, critical processes in tumor growth and metastasis.
- PD-L1 Pathway Enrichment: The PD-L1 expression and PD-1 checkpoint pathway in cancer is positively enriched in multiple tumor-associated cell types, including Intestinal Epithelial cells, CD4+ T cells, CD8+ T cells, and Macrophages, highlighting potential immune evasion mechanisms.
- Ploidy-Related Differences: For Intestinal Epithelial cells, the "Diploid_vs_others" comparison shows a contrasting pattern to "tumor_vs_others" for several proliferation-related pathways, implying distinct biological states potentially linked to ploidy.
Biological Interpretation
The GSEA results provide a comprehensive view of the biological programs activated within specific cell types in the colon tumor microenvironment.
- Intestinal Epithelial Cell Malignancy: The strong enrichment of Cell cycle, DNA replication, Pathways in cancer, Ribosome biogenesis in eukaryotes, and Proteasome in tumor-associated Intestinal Epithelial cells is a direct signature of uncontrolled proliferation, increased metabolic demand, and protein synthesis characteristic of malignant transformation. The negative enrichment of pathways like Focal adhesion might indicate a shift towards a less adhesive, more migratory phenotype conducive to invasion and metastasis [GeneCards: CADHERIN1]. The enrichment of PD-L1 expression and PD-1 checkpoint pathway in cancer in these cells suggests a mechanism by which tumor cells evade immune surveillance by expressing PD-L1, leading to T cell exhaustion.
- Inflammatory and Adaptive Immune Response: T cells (CD4+ and CD8+) and Macrophages in the tumor microenvironment show pronounced activation of pathways involved in immune signaling and inflammation, including Antigen processing and presentation, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, NF-kappa B signaling pathway, and Th1 and Th2 cell differentiation. This indicates an active immune response, where these cells are engaged in sensing and responding to tumor antigens. However, the concurrent enrichment of the PD-L1 expression and PD-1 checkpoint pathway in cancer in these immune cells suggests potential immune dysfunction or exhaustion within the tumor microenvironment, where chronic stimulation or suppressive signals can lead to impaired effector function [PubMed: T cell exhaustion]. Macrophages further show strong enrichment for Phagosome and Fc gamma R-mediated phagocytosis, reflecting their role in engulfing cellular debris and pathogens, which can be altered in the tumor context, potentially contributing to pro-tumorigenic functions (e.g., M2-like macrophages).
- Tumor Microenvironment Remodeling:
- Fibroblasts (CAFs): Tumor-associated Fibroblasts exhibit strong enrichment for Focal adhesion, ECM-receptor interaction, PI3K-Akt signaling pathway, MAPK signaling pathway, Proteoglycans in cancer, and TGF-beta signaling pathway. These pathways are hallmarks of Cancer-Associated Fibroblasts (CAFs), which are crucial for extracellular matrix (ECM) remodeling, promoting tumor invasion, angiogenesis, and immunosuppression [GeneCards: TGFB1].
- Endothelial Cells: Endothelial cells in the tumor are highly enriched for VEGF signaling pathway, Focal adhesion, PI3K-Akt signaling pathway, and MAPK signaling pathway. This profile clearly indicates active angiogenesis—the formation of new blood vessels—which is essential for supplying nutrients and oxygen to the rapidly growing tumor and facilitating metastasis [GeneCards: VEGFA].
- Broader Immune Cell Activation: B cells and Mast cells in the tumor environment also display activation of general immune signaling pathways like Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, and NF-kappa B signaling pathway. B cells specifically show B cell receptor signaling pathway and Antigen processing and presentation enrichment. Mast cells show Fc epsilon RI signaling pathway enrichment, suggesting their activation and potential contribution to the inflammatory milieu or immune modulation within the tumor. The positive enrichment of Intestinal immune network for IgA production in B cells across both tumor and normal conditions underscores the unique immunological context of the colon.
- Ploidy Implications: The distinct GSEA profile for "Intestinal Epithelial cell: Diploid_vs_others" highlights that ploidy status, as indicated by ploidy_dec, is associated with different cellular states and pathway activities within the Intestinal Epithelial cell compartment. Diploid epithelial cells might represent a less transformed or quiescent population compared to aneuploid tumor cells, which typically show higher proliferative and oncogenic pathway activities.
Clinical or Translational Implications
The GSEA results provide several insights with potential clinical and translational implications for colon cancer:
- Immune Checkpoint Blockade: The consistent enrichment of PD-L1 expression and PD-1 checkpoint pathway in cancer across tumor Intestinal Epithelial cells, T cells, and Macrophages strongly suggests that PD-1/PD-L1 axis blockade could be a relevant therapeutic strategy for a subset of colon cancers, particularly those exhibiting high immune infiltration and immune evasion mechanisms [PubMed: PD-1/PD-L1 immunotherapy colon cancer]. Identifying the specific cell types driving PD-L1 expression could help stratify patients for immunotherapeutic interventions.
- Targeting Tumor Microenvironment: Pathways enriched in Fibroblasts (Focal adhesion, ECM-receptor interaction, TGF-beta signaling pathway) and Endothelial cells (VEGF signaling pathway) highlight the importance of the tumor microenvironment. Targeting CAFs or angiogenesis (e.g., anti-VEGF therapies) could be effective in inhibiting tumor growth and metastasis in colon cancer [PubMed: Angiogenesis inhibitors colon cancer].
- Inflammation as a Therapeutic Target: The widespread activation of inflammatory and signaling pathways (e.g., JAK-STAT, NF-kappa B, MAPK, Cytokine-cytokine receptor interaction) in various immune and stromal cells underscores the pro-tumorigenic role of chronic inflammation in colon cancer. Therapies aimed at modulating these inflammatory pathways could have broad anti-tumor effects [PubMed: Inflammation colon cancer].
- Cell Cycle and Proliferation: The prominent enrichment of cell cycle and DNA replication pathways in tumor Intestinal Epithelial cells reinforces the utility of conventional chemotherapies that target rapidly dividing cells. However, understanding the specific regulatory mechanisms might lead to more targeted anti-proliferative agents with reduced off-target effects.
- Biomarker Discovery: The distinct pathway signatures for tumor vs. adjacent normal cells within each cell type could serve as a rich resource for identifying novel diagnostic or prognostic biomarkers. For example, specific gene sets highly enriched in tumor-associated CAFs or macrophages could indicate disease progression or response to therapy.
- Understanding Aneuploidy in Cancer: The ploidy-associated pathway differences in Intestinal Epithelial cells suggest that considering cellular ploidy might be important for understanding tumor heterogeneity and predicting treatment response. This could guide further investigation into aneuploidy-specific vulnerabilities.
23. Discussion
The single-cell analysis of colon tissue reveals a deeply reprogrammed cellular landscape in tumor versus adjacent normal conditions. A central finding is the robust identification of malignant epithelial cells through their distinctive aneuploid status and widespread upregulation of cell cycle genes, alongside amplifications of oncogenes such as *EGFR*, *ERBB2*, and the *MYC* locus. These malignant epithelial cells also exhibit unique surfaceome signatures, including upregulation of *MET*, *RNF43*, and various solute carrier proteins, indicating profound metabolic and surface receptor remodeling for tumor growth and survival.
The tumor immune microenvironment is characterized by a significant infiltration of T cells and macrophages. While T cell populations show a depletion of naive cells and an enrichment of immunosuppressive subsets like regulatory T cells (Tregs), Th22, and ILCreg cells, there is also evidence of active engagement, indicated by co-stimulatory and inhibitory immune checkpoint interactions on CD4+ T cells (e.g., CTLA4, TIGIT, OX40, GITR). Macrophages exhibit a complex polarization, with an overall shift towards M2-like phenotypes, yet surprisingly, an increased proportion of M1 macrophages in tumor tissue compared to adjacent normal, suggesting a dynamic and heterogeneous immune response. Tumor-associated macrophages (TAMs) also express a distinct surfaceome, including pro-tumorigenic markers like SIRPA, CD44, and HBEGF, crucial for immune evasion and tumor progression.
Cancer-associated fibroblasts (CAFs) are significantly expanded in the tumor and display a highly activated phenotype, characterized by unique surface markers such as PDGFRB, ITGAV, and ANTXR1, and extensively engage in extracellular matrix remodeling and pro-angiogenic signaling pathways. Cell-cell interaction analysis further highlights this complex interplay, with enhanced TGF-β, CXCL12-CXCR4, SPP1-integrin, and MIF-CD74 signaling, fostering an immunosuppressive and pro-tumorigenic milieu. Moreover, prominent angiogenesis pathways (VEGFA-KDR/FLT1, PDGFD-PDGFRB, DLL4-NOTCH3, PGF-NRP2) are activated in endothelial and fibroblast populations, supporting sustained tumor growth.
An intriguing finding is the presence of aneuploid epithelial cells within some adjacent normal samples. This suggests a potential field cancerization effect or early clonal evolution, indicating a pre-malignant state or subtle genomic instability even in macroscopically normal tissue. The consistent enrichment of the PD-L1 checkpoint pathway across multiple tumor-associated cell types (epithelial, T cells, macrophages) underscores its critical role in immune evasion in this cohort. Overall, the study provides a high-resolution map of colorectal cancer heterogeneity, identifying key cellular and molecular drivers of disease progression and offering a robust foundation for identifying novel therapeutic strategies.
Hypotheses:
- Aneuploid intestinal epithelial cells in colon tumors are the primary malignant cells, exhibiting increased proliferation and altered surface receptor expression that drives tumor growth and immune evasion.
- The increase in Tregs, Th22, and ILCreg T cell subsets, alongside specific macrophage polarization (M2-like) and active immune checkpoint signaling (CTLA4, TIGIT, PD-L1), establishes a highly immunosuppressive microenvironment in colon cancer, hindering effective anti-tumor immunity.
- Cancer-associated fibroblasts (CAFs) in colon tumors undergo significant activation and express a distinct surfaceome, driving extracellular matrix remodeling, angiogenesis, and providing pro-tumorigenic support through specific cell-cell interactions.
- The presence of aneuploid epithelial cells in histologically normal adjacent tissue represents an early stage of genomic instability and clonal evolution, contributing to field cancerization and increased risk for tumor recurrence or progression.
- Tumor epithelial cells and tumor-associated macrophages (TAMs) undergo significant metabolic reprogramming, as evidenced by upregulation of solute carrier (SLC) family genes and enrichment of metabolism pathways, supporting their high energetic and biosynthetic demands.
Potential therapeutic targets:
- TGF-β Signaling Pathway: Consistently and strongly activated in the tumor microenvironment (macrophages to intestinal epithelial cells, various cell-cell interactions), contributing to immune suppression, fibrosis, and tumor progression in colorectal cancer. Evidence: Analysis sections 12, 13, 14, 15, and 22 (GSEA shows TGF-beta signaling pathway enriched in fibroblasts) highlight robust TGFB1-TGFBR1/2 interactions in tumor conditions. Validation: Inhibit TGF-β signaling (e.g., using small molecule inhibitors or neutralizing antibodies) in patient-derived organoid-immune co-culture models or xenografts to assess effects on tumor growth, ECM remodeling, and immune cell function (e.g., T cell proliferation/cytotoxicity, macrophage polarization). Combine with immune checkpoint inhibitors.
- SIRPA-CD47 Axis: SIRPA is highly upregulated on tumor-associated macrophages (TAMs). Its interaction with CD47 on cancer cells provides a 'don't eat me' signal, inhibiting macrophage-mediated phagocytosis and promoting immune evasion. Evidence: Analysis section 17 demonstrates significant upregulation of SIRPA on tumor macrophages compared to adjacent normal counterparts. Validation: Use anti-SIRPA or anti-CD47 blocking antibodies in in vitro phagocytosis assays with sorted tumor cells and TAMs, and in vivo in syngeneic or humanized mouse models to demonstrate enhanced tumor cell clearance and anti-tumor immunity.
- MET Receptor Tyrosine Kinase: MET is significantly upregulated on malignant intestinal epithelial cells, known to drive cell proliferation, survival, migration, and invasion in various cancers, including colorectal cancer. Evidence: Analysis section 16 identifies MET as a prominent and highly upregulated surfaceome marker in tumor-associated intestinal epithelial cells. Validation: Test MET inhibitors (e.g., capmatinib, tepotinib) in patient-derived colon cancer organoids or xenograft models with high MET expression. Assess effects on tumor growth, invasion, and metastasis.
- Immune Checkpoints (CTLA4, TIGIT, PD-L1 pathway): CTLA4 and TIGIT are upregulated on activated/exhausted CD4+ T cells, and the PD-L1 checkpoint pathway is consistently enriched across tumor epithelial cells, T cells, and macrophages, indicating active immune evasion mechanisms in the tumor microenvironment. Evidence: Analysis section 14 shows CD274 (PD-L1)-CD80 interactions. Section 19 identifies upregulation of CTLA4 and TIGIT on CD4+ T cells. Section 22 reveals consistent enrichment of the 'PD-L1 expression and PD-1 checkpoint pathway in cancer' in multiple tumor-associated cell types. Validation: Administer checkpoint inhibitors (e.g., anti-CTLA4, anti-TIGIT, anti-PD-L1) as monotherapy or in combination in syngeneic or humanized mouse models of colon cancer, assessing changes in T cell function, tumor growth, and survival. Validate in clinical trials for specific patient subsets.
Follow-up validation ideas:
- Confirm aneuploidy at the single-cell level using FISH or targeted DNA sequencing on sorted epithelial cells from tumor and adjacent normal tissues.
- Validate differential protein expression of MET, RNF43, SLCs, and ITGA2 in malignant epithelial cells within tumor tissue sections using immunostaining or spatial transcriptomics.
- Perform in vitro (organoids, 3D culture) and in vivo (patient-derived xenografts) perturbation assays to assess the functional impact of targeting candidate genes on epithelial cell proliferation, survival, and invasiveness.
- Quantify and localize Treg, Th22, ILCreg, and specific macrophage subsets (M1/M2 markers, SIRPA) in larger patient cohorts using flow cytometry or immunostaining.
- Assess the suppressive function of tumor-infiltrating Tregs on effector T cells, and the pro-tumorigenic activity of TAMs (e.g., cytokine secretion, phagocytosis, T cell inhibition) using functional assays ex vivo.
- Perform functional perturbation assays, such as blockade of CTLA4, TIGIT, PD-L1, or SIRPA-CD47 using antibodies or genetic tools in co-culture models or humanized mouse models, to evaluate restoration of anti-tumor immunity.
- Validate expression of PDGFRB, ITGAV, ANTXR1, and CDH11 in CAFs within tumor sections using immunostaining or spatial transcriptomics, assessing their spatial proximity to tumor cells.
- Evaluate the impact of targeting CAF-specific markers (e.g., PDGFRB inhibitors, integrin blockade) on ECM remodeling, tumor cell invasion, and angiogenesis using 3D co-culture models or patient-derived xenografts.
- Confirm key ligand-receptor interactions like PDGFD-PDGFRB, COL-integrin, LAMC1-integrin in co-culture systems using reporter assays or antibody blockade.
- Analyze CNV in a larger cohort of adjacent normal tissue samples from colon cancer patients and healthy controls to confirm the prevalence and extent of aneuploidy, potentially through bulk or single-cell sequencing.
- Perform targeted metabolomics or stable isotope tracing on sorted tumor epithelial cells and TAMs to validate altered metabolic pathways (e.g., glucose uptake, amino acid metabolism).
- Inhibit specific SLC transporters (e.g., SLC1A5, SLC2A3) in tumor cells or TAMs to assess their impact on proliferation, survival, and immune functions.
Limitations:
This single-cell analysis provides comprehensive insights into colon cancer, yet it is subject to several limitations. The observational nature of transcriptomic data prevents direct inference of causality for the identified cellular and molecular alterations. Significant inter-sample heterogeneity was observed, particularly in CNV profiles and cell population proportions, suggesting that findings may not generalize to all colorectal cancer patients. Cell type annotations, while robust, are based on known markers and reference datasets, and the presence of 'unassigned' populations indicates remaining cellular complexity or uncharacterized states. Furthermore, CNV and ploidy estimations are inferred and warrant orthogonal genomic validation. The current dataset provides a static snapshot of the tumor microenvironment, which is a dynamic system; thus, these findings represent specific states at the time of sampling. While surfaceome markers are excellent therapeutic targets, limiting some marker analyses to the surfaceome may overlook important intracellular targets or signaling pathways. Finally, potential technical biases related to tissue dissociation, RNA capture efficiency, and bioinformatic processing, though addressed by data integration, are inherent to single-cell studies.
24. Query List
- Show UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset, in 2 columns and save.
- Show the expression of CD3D, CD4, CD8A, CD79A, MS4A1, MZB1, CD14, LYZ, FBLN1, NOTCH3, EPCAM, MUC1, CD34 genes on UMAP, along with minor celltype annotation. Set ncols=4 and save.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Select Intestinal Epithelial cells and unassigned cells, group them by sample, show a CNV heatmap, and include a summary of significantly amplified copy number regions. Save.
- Show CNV patterns on UMAP, including major cell type, minor cell type, ploidy results, condition, and sample, in 2 columns and save.
- Show a population bar plot for minor cell types and save.
- Show a subset population barplot for T cells and save.
- Show a subset population barplot for Macrophage cells and save.
- Show boxplots for T cell subset populations if there are statistically significant differences between conditions, and save. Determine ncols appropriately based on the total number of panels.
- Show boxplots for Macrophage subset populations if there are statistically significant differences between conditions, and save. Determine ncols appropriately based on the total number of panels.
- Select Intestinal Epithelial cells and unassigned cells, and show a bar plot of their ploidy population. Save.
- Show cell-cell interaction patterns by condition, including tumor-origin cells (Intestinal Epithelial cells), fibroblasts, macrophages, and T cells. Select up to 80 cell-cell interactions per condition. Save.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Select only genes related to immune checkpoint and cell cycle pathways, and show cell-cell interactions for these genes. Save.
- Find statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells, and show them as a dot plot. Set max_n_items_per_group = 25 and save.
- Show the condition-specific markers for tumor-origin cells (Intestinal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract condition-specific markers for Macrophage cells and show them as a dot plot. Include only surfaceome markers, up to 50 per condition, and save.
- Extract condition-specific markers for Fibroblast cells and show them as a dot plot. Include only surfaceome markers, up to 50 per condition, and save.
- Extract condition-specific markers for CD4 T cells and show them as a dot plot. Include only surfaceome markers, up to 50 per condition, and save.
- Select cell cycle pathway-related genes with statistically significant differences in expression between conditions for major disease-relevant cells, and show boxplots. Set max_n_items_to_plot = 24 and determine ncols appropriately so that the width-to-height ratio is about 2x3 for the entire panel. Save.
- Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
- Show a dot plot of Gene Set Enrichment Analysis results for major cell types. Use the RdBu_r color map and set n_pws_to_show = 80. Save.





















